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ABSTRACT
Background
Inclusion body myositis (IBM) is a late-onset inflammatory muscle disease (myopathy) associated with progressive proximal and distal
limb muscle atrophy and weakness. Treatment options have attempted to target inflammatory and atrophic features of this condition
(for example with immunosuppressive and immunomodulating drugs, anabolic steroids, and antioxidant treatments), although as yet
there is no known effective treatment for reversing or minimising the progression of inclusion body myositis. In this review we have
considered the benefits, adverse effects, and costs of treatment in targeting cardinal effects of the condition, namely muscle atrophy,
weakness, and functional impairment.
Objectives
To assess the effects of treatment for IBM.
Search methods
On 7 October 2014 we searched the Cochrane Neuromuscular Disease Group Specialized Register, the Cochrane Central Register for
Controlled Trials (CENTRAL), MEDLINE, and EMBASE. Additionally in November 2014 we searched clinical trials registries for
ongoing or completed but unpublished trials.
Selection criteria
We considered randomised or quasi-randomised trials, including cross-over trials, of treatment for IBM in adults compared to placebo
or any other treatment for inclusion in the review. We specifically excluded people with familial IBM and hereditary inclusion body
myopathy, but we included people who had connective tissue and autoimmune diseases associated with IBM, which may or may not
be identified in trials. We did not include studies of exercise therapy or dysphagia management, which are topics of other Cochrane
systematic reviews.
Treatment for inclusion body myositis (Review)
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Data collection and analysis
We used standard Cochrane methodological procedures.
Main results
The review included 10 trials (249 participants) using different treatment regimens. Seven of the 10 trials assessed single agents, and 3
assessed combined agents. Many of the studies did not present adequate data for the reporting of the primary outcome of the review,
which was the percentage change in muscle strength score at six months. Pooled data from two trials of interferon beta-1a (n = 58)
identified no important difference in normalised manual muscle strength sum scores from baseline to six months (mean difference
(MD) -0.06, 95% CI -0.15 to 0.03) between IFN beta-1a and placebo (moderate-quality evidence). A single trial of methotrexate
(MTX) (n = 44) provided moderate-quality evidence that MTX did not arrest or slow disease progression, based on reported percentage
change in manual muscle strength sum scores at 12 months. None of the fully published trials were adequately powered to detect a
treatment effect.
We assessed six of the nine fully published trials as providing very low-quality evidence in relation to the primary outcome measure.
Three trials (n = 78) compared intravenous immunoglobulin (combined in one trial with prednisone) to a placebo, but we were unable
to perform meta-analysis because of variations in study analysis and presentation of trial data, with no access to the primary data
for re-analysis. Other comparisons were also reported in single trials. An open trial of anti-T lymphocyte immunoglobulin (ATG)
combined with MTX versus MTX provided very low-quality evidence in favour of the combined therapy, based on percentage change
in quantitative muscle strength sum scores at 12 months (MD 12.50%, 95% CI 2.43 to 22.57). Data from trials of oxandrolone versus
placebo, azathioprine (AZA) combined with MTX versus MTX, and arimoclomol versus placebo did not allow us to report either
normalised or percentage change in muscle strength sum scores. A complete analysis of the effects of arimoclomol is pending data
publication. Studies of simvastatin and bimagrumab (BYM338) are ongoing.
All analysed trials reported adverse events. Only 1 of the 10 trials interpreted these for statistical significance. None of the trials included
prespecified criteria for significant adverse events.
Authors’ conclusions
Trials of interferon beta-1a and MTX provided moderate-quality evidence of having no effect on the progression of IBM. Overall trial
design limitations including risk of bias, low numbers of participants, and short duration make it difficult to say whether or not any of
the drug treatments included in this review were effective. An open trial of ATG combined with MTX versus MTX provided very lowquality evidence in favour of the combined therapy based on the percentage change data given. We were unable to draw conclusions
from trials of IVIg, oxandrolone, and AZA plus MTX versus MTX. We need more randomised controlled trials that are larger, of
longer duration, and that use fully validated, standardised, and responsive outcome measures.

PLAIN LANGUAGE SUMMARY
Therapy for inclusion body myositis
Review question
We reviewed the evidence from clinical trials about the effects of drug treatments for inclusion body myositis (IBM). We did not include
trials of exercise or management of swallowing difficulties, as these are subjects of other Cochrane reviews.
Background
IBM is a disease that mainly affects older people. The main symptoms are increasing muscle wasting and weakness of the arms and
legs. Some people experience swallowing difficulties. As yet no therapy has been shown to alter the course of the disease. Treatments
that have been tested include agents that suppress or alter the immune response, drugs that promote muscle growth, and antioxidants.
Study characteristics
This review included 10 trials (249 participants). One of these trials (24 participants) is completed but has not yet been published.
Seven trials compared treatments with placebo (inactive treatment): three of intravenous immunoglobulin (IVIg), two of interferon
beta-1a (IFN beta-1a), and one each of oxandrolone, methotrexate (MTX), and arimoclomol (not yet published). A further two trials
compared MTX with combined immunosuppressive therapy (MTX with anti-T lymphocyte immunoglobulin (ATG) (an agent that
Treatment for inclusion body myositis (Review)
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destroys white blood cells) and MTX with azathioprine). In these two trials, participants and investigators knew which treatment
participants were receiving, which could have biased the results.
Results and quality of the evidence
For our primary outcome, which was muscle strength, we were only able to combine the results for the two trials of IFN beta-1a
therapy versus placebo. This treatment did not appear to offer a benefit in terms of muscle strength. MTX also did not stop or retard
loss of muscle strength when compared to placebo. We considered the evidence from these trials to be of moderate quality because
the trials were too small to rule out a possible benefit for these drugs. For the other trials, the evidence was of very low quality. Three
trials compared IVIg (combined in one trial with prednisone) to a placebo, but we were unable to perform meta-analysis because the
available data were not suitable. One trial of ATG combined with MTX versus MTX alone provided very low-quality evidence of an
effect on muscle strength in favour of MTX plus ATG at 12 months. The other comparisons, of MTX versus placebo, oxandrolone
versus placebo, azathioprine combined with MTX versus MTX, and arimoclomol versus placebo were reported in single trials that did
not provide enough data for analysis of the effect on muscle strength.
Due to their small size and short duration, the trials we studied were generally unable to give definitive answers as to whether the
treatments tested were effective or ineffective. All of the interventions we studied had some adverse effects and are known to cause
potentially serious adverse events. We need larger trials of longer duration, using robust ways of measuring the effects of treatments
that are meaningful to people with IBM. Agreeing on common trial measurements will also make it easier to compare trial results and
assess potential treatments.
The evidence is current to October 2014.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]

Intravenous immunoglobulin versus placebo for inclusion body myositis
Patient or population: people with inclusion body myositis
Settings:
Intervention: intravenous immunoglobulin
Comparison: placebo
Outcomes

Illustrative comparative risks* (95% CI)

Assumed risk

Corresponding risk

Placebo

Intravenous
immunoglobulin

Relative effect
(95% CI)

No of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Change
in
muscle Not estimable
strength at 6 months (%)

Not estimable

Not estimable

78
(3 studies)

See comment

2 of the 3 studies assessed change in muscle strength at 3 months
and the other at 6 months.
Data were not suitable for
meta-analysis

Change
in
muscle strength at 12 months
(%) - not measured

-

-

-

-

-

Change in muscle mass at 6 months (%) - not
measured

-

-

-

-

-

Change in handgrip strength at 6 months (%)
- not measured

-

-

-

-

-
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Change in timed walk at 6 months (%)
e.g. 10-metre or 6-minute
walk test at 6 months not measured

-

-

-

-

-

Significant
events

Not estimable

Not estimable

78 (3 studies)

See comment

Dalakas 1997: unclear
whether dropouts from
treatment or placebo
group. Dalakas 2001:
treatment group withdrawals = 0; placebo
group withdrawals = 1.
Walter 2000: 2 withdrawals but unspecified
whether from treatment or
placebo group

adverse Not estimable

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
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BACKGROUND

Description of the condition
Inclusion body myositis (IBM) is a late-onset inflammatory muscle disease (myopathy) with a distinctive pattern of proximal and
distal limb atrophy and weakness. IBM is considered to be the
most common acquired myopathy in those over age 50. In early
published series, IBM has accounted for up to 28% of all idiopathic inflammatory myopathies, although the true proportion
could be much higher (Lotz 1989). In the Netherlands, prevalence has been estimated at 4.9 per million inhabitants (Badrising
2000). Between 2000 and 2008, prevalence in Western Australia
rose from 9.3 to 14.9 per million inhabitants, a change attributed
to improved case identification (Needham 2008; Phillips 2000).
Prevalence adjusted for age over 50 years is higher, up to 51.3 per
million population (Needham 2008).
IBM is usually a sporadic and isolated disorder that can be associated with secondary mitochondrial DNA abnormalities in excess
of those seen with normal ageing (Oldfors 1995). In rare instances,
typical IBM occurs in families (Amato 1998; Tateyama 2003);
this familial IBM should not be confused with hereditary inclusion body myopathy, which is not usually associated with inflammation and in which there may be mutations in the GNE gene
(Huizing 2009). IBM is sometimes associated with a variety of
connective tissue and autoimmune diseases, including rheumatoid
arthritis (Soden 1994), vitamin B12 deficiency (Khraishi 1992),
Sjögren’s syndrome (Gutmann 1985; Khraishi 1992), chronic immune thrombocytopenia (Riggs 1984), sarcoidosis (Danon 1986),
collagen vascular disease (Lane 1985), and common variable immune deficiency (Dalakas 1995; Lindberg 1990).
To date, clinicopathologically defined criteria for sporadic IBM,
as proposed by Griggs 1995 and revised by Benveniste 2010 and
Hilton-Jones 2010, have formed the basis for diagnostic criteria. Improved case ascertainment through clinical assessment has
supported the application of clinically defined diagnostic criteria. However, for the purpose of reviewing the existing clinical
trials, we included those trials using clinicopathologically defined
sporadic IBM, as defined by Griggs 1995, Benveniste 2010, or
Hilton-Jones 2010.

flexors can impair handgrip, while quadriceps weakness can cause
knee instability, making rising from chairs, managing stairs, and
walking increasingly difficult. For the purpose of this review, it
seemed reasonable to choose those outcome measures assessing the
cardinal effects of IBM, namely muscle atrophy, weakness, and
functional impairment.
In terms of atrophy, muscle mass can be measured in a number of
ways, including:
1. urinary creatinine excretion under controlled conditions;
2. potassium isotope counting;
3. magnetic resonance imaging (MRI);
4. computerised tomography (CT) muscle imaging; and
5. dual energy X-ray absorptiometry (DEXA).
Muscle strength can be measured manually (referred to as manual
muscle testing, or MMT) and is commonly scored using the sixpoint Medical Research Council (MRC) strength scale or modified MRC scale. Alternatively, the maximal voluntary isometric
contraction or isokinetic muscle strength can be measured using
a hand-held or fixed myometer (referred to as quantitative muscle
testing (QMT)) and the results expressed in units of force (newtons, kilograms, or pounds). However, as with MMT, the selected
muscles tested by QMT can vary; QMT sum scores are often expressed as the z-score, which is the sum of the standard deviations
from the mean for each muscle tested.
In terms of measuring functional impairment, single-item tests
include timed walking tests, stair climb, and rise from chair; we
have chosen timed walking tests as appropriate measures for the
patient population in this review. There are also questionnaire
based, multi-item rating scales, such as the IBM Functional Rating
Scale, that provide an overall score across different functional tasks
(Jackson 2008). In choosing appropriate outcome measures for
this review, we also wanted to consider other patient reported
outcome measures, including symptom severity and quality of life,
as well as adverse events associated with treatment. However, these
outcome measures are not consistently applied across different
muscle disease centres and trials at present.
We can specify a minimum time period for the primary outcome
measure in relation to its sensitivity to change in a slowly progressive condition. Power calculations based upon available natural
history data for muscle strength in IBM support a minimum trial
length of six months (Rose 2001).

Potential outcome measures
The muscle atrophy and weakness of IBM usually follow a slowly
progressive course. In the absence of established effective drug
treatment, the mainstay of treatment is supportive. Natural history
studies suggest that people with IBM can experience a 3.5% to
5.2% annual decline in compound muscle strength graded manually (Cortese 2013; Cox 2011). Because of its characteristic pattern of muscle involvement, IBM may cause predictable functional
difficulties. For example, weakness of the long (extrinsic) finger

Description of the intervention
Interventions included pharmacological agents, dietary supplements, and musculoskeletal surgery. We excluded the management
of dysphagia and the role of exercise therapy for muscle disease,
which other Cochrane systematic reviews of interventions discuss
(Hill 2004; Voet 2013).

Treatment for inclusion body myositis (Review)
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Why it is important to do this review
As the first systematic review of treatment for IBM, this Cochrane
review aimed to determine the evidence base for current treatment
and to identify dose-responses where possible. Our findings may
also be relevant to other neuromuscular and age-related conditions
in which muscle weakness, atrophy, and inflammation are prominent symptoms.

Therapies were administered using various protocols including as
single agents, combined therapy, or sequential therapy. We analysed different interventions separately.
Types of outcome measures

Primary outcomes

OBJECTIVES

The primary outcome measure for this review was percentage
change in muscle strength (using MMT or QMT) from baseline
at six months.

To systematically assess the effects of treatment for IBM.
Secondary outcomes

METHODS

Criteria for considering studies for this review
Types of studies
We considered for inclusion randomised or quasi-randomised trials, including cross-over trials, of treatment for IBM (except for
exercise therapy and dysphagia management). We included comparisons of treatment versus placebo or any other treatment. We
included studies reported as full text, those published as abstract
only, and unpublished data, with no language restrictions.
Types of participants
All participants were over 18 years of age and had a clinicopathologically defined diagnosis of IBM (Benveniste 2010; Griggs 1995;
Hilton-Jones 2010). We specifically excluded people with familial
IBM and hereditary inclusion body myopathy, but we included
people who had connective tissue and autoimmune diseases associated with IBM, which may or may not be identified in trials.
Types of interventions
We included the following interventions.
1. Immunosuppressive agents, e.g. prednisolone (and other
corticosteroids), cyclophosphamide, chlorambucil, azathioprine,
methotrexate (MTX), and ciclosporin.
2. Immunomodulatory interventions, e.g. intravenous
immunoglobulin, leukopheresis, plasma exchange, and immunetargeted monoclonal antibodies.
3. Antioxidants, e.g. vitamin E.
4. Mitochondrial substrates, e.g. carnitine and ubiquinone.
5. Anabolic steroids and muscle supplements.
6. Other interventions except for exercise therapy and
dysphagia management.

Secondary outcome measures for this review were as follows.
1. Percentage change from baseline in muscle strength (using
MMT or QMT) at 12 months.
2. Percentage change from baseline in handgrip strength at 6
months.
3. Percentage change from baseline in muscle mass (by
whatever method, e.g. MRI) at 6 months.
4. Percentage change from baseline in timed walk (e.g. 10metre or 6-minute walk) at 6 months.
5. Significant adverse events from the intervention.*
We evaluated QMT only when the trial did not use MMT for
muscle testing.
Where relevant data were available we considered the costs of interventions in the Discussion.
*An ‘adverse event’ is defined as an adverse outcome that occurs
during or after the use of a drug or other intervention but is not
necessarily caused by it (Cochrane 2015).

Search methods for identification of studies

Electronic searches
On 7 October 2014, the Trials Search Co-ordinator searched
the Cochrane Neuromuscular Disease Group Specialized Register,
the Cochrane Central Register for Controlled Trials (CENTRAL,
2014, Issue 9 in the Cochrane Library), MEDLINE (January 1966
to September 2014), and EMBASE (January 1947 to September
2014). Detailed search strategies are in the appendices: Cochrane
Neuromuscular Disease Group Specialized Register (Appendix 1),
CENTRAL (Appendix 2), MEDLINE (Appendix 3), and EMBASE (Appendix 4).
We searched all databases from their inception to the present, and
we imposed no restriction on language of publication.
In
November
2014,
we
searched
ClinicalTrials.gov (clinicaltrials.gov) and the World Health Organization
International Clinical Trials Registry Platform (ICTRP) (who.int/

Treatment for inclusion body myositis (Review)
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trialsearch/) for ongoing trials and completed unpublished studies
using the search term ‘inclusion body myositis’.
Searching other resources
We checked references in the identified trials and contacted trial
authors to identify any additional published or unpublished data.
In 1999, the review authors scanned conference abstracts including those of the American Academy of Neurology, the International Conference on Neuromuscular Diseases, the World Muscle
Society, and the European Neurological Society for relevant studies but did not update this search.

Data collection and analysis
At least two review authors (from among JM, KJ, KL, MW, MR
and RB) extracted data and resolved any discrepancies by discussion. We contacted the authors of the trials to provide missing data
where possible.

reach a judgement or when, despite knowing what occurred in the
study, the risk of bias remained unclear. We also examined whether
studies included explicit diagnostic criteria, validation of outcome
measurements, and power calculations to detect statistical benefit.
Where we were uncertain, we contacted trial authors for clarification. The review authors resolved any disagreements over ‘Risk of
bias’ assessment by consensus. We conducted the review according
to the published protocol (Rose 2014), reporting any deviations
from it in Differences between protocol and review.

Measures of treatment effect
We analysed dichotomous data as a risk ratio with a 95% confidence interval (CI). We analysed continuous data as the mean
difference, or standardised mean difference with 95% CI when
outcomes were conceptually the same but measured in different
ways. We calculated a treatment effect through random-effects
meta-analysis, using RevMan 5 (RevMan 2014).

Selection of studies

Unit of analysis issues

At least two review authors (from among MR, KJ, MW, and JM)
examined the papers identified by the search strategy for studies eligible for inclusion. The review authors independently confirmed
that studies were randomised or quasi-randomised trials and that
diagnostic criteria for IBM had been met.

Included studies determined compound muscle strength using different muscle groups, which represented a potential unit of analysis error. The carry-over effect of sequential intervention in crossover trials was another potential source of unit of analysis error.
There was also a possible learning effect in the primary outcome
of interest, muscle strength, that we would have considered in particular for cross-over trials if they had provided data suitable for
analysis.

Data extraction and management
At least five review authors (from among MR, KJ, KL, MW, JM,
and RB) independently performed data extraction using a specially designed data extraction form. The review authors contacted
authors of included trials to provide missing data where possible. One or two review authors checked and entered data into
the Cochrane authoring and statistical software, Review Manager
(RevMan) 5 (MR and KL) (RevMan 2014); another review author checked the data entry (KJ). A non-conflicted review author
performed data extraction independently if any review author had
potential conflicts of interest, for example through involvement
in an included study.

Dealing with missing data
We contacted investigators in order to verify key study characteristics and to obtain missing numerical outcome data where possible
(such as when a study was only available as an abstract). Where
this was not possible, and we thought that missing data introduced
serious bias, we explored the impact of including such studies.

Assessment of heterogeneity
Assessment of risk of bias in included studies
Two review authors (MR and KJ) independently assessed the risk
of bias in included studies using the following criteria: sequence
generation, allocation concealment, blinding of participants and
personnel, blinding of outcome assessors, incomplete outcome
data, selective outcome reporting, and other risk of bias. The review authors identified high, low, or unclear risk of bias for each
trial according to criteria described in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011). We used
the ‘unclear’ rating when there was insufficient information to

We used the I² statistic to measure heterogeneity among the trials
in each analysis. If we identified any substantial unexplained heterogeneity, we planned to report this and to explore the possible
causes by prespecified subgroup analysis.

Assessment of reporting biases
We were not able to pool enough trials (that is more than 10) to
create and examine a funnel plot to explore possible small-study
biases.

Treatment for inclusion body myositis (Review)
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Data synthesis

Description of studies

We used a random-effects model on the assumption that the included studies estimated different but related intervention effects.
We applied a fixed-effect model to further consider the presence of
any heterogeneity among included studies. As the review included
several comparisons that could not be combined in the same analysis, we reported the results for each comparison separately.

The search strategies in the Appendices produced the following results: Cochrane Neuromuscular Disease Group Specialized
Register 23 records, CENTRAL 26 records, MEDLINE 273
records, and EMBASE 95 records. In total, the review authors
identified 24 studies, with 10 fulfilling the inclusion criteria; see
Characteristics of included studies. We excluded 14 studies (4 ongoing) because they were not randomised controlled trials (RCTs);
see Characteristics of excluded studies.
The interventions used among the 10 trials identified for inclusion were: intravenous immunoglobulin (IVIg) (Dalakas 1997;
Dalakas 2001; Walter 2000); interferon beta-1a (IFN beta1a) (Muscle Study Group 2001; Muscle Study Group 2004);
methotrexate (MTX) (Badrising 2002); an anabolic steroid (oxandrolone) (Rutkove 2002); and arimoclomol (Machado 2013).
All of these trials compared the intervention, used on its own,
to placebo. The remaining two trials compared combination
immunosuppressive therapy (MTX and anti-T lymphocyte immunoglobulin (ATG) (Lindberg 2003); and MTX and azathioprine (AZA) (Leff 1993)) to an MTX treatment regimen.
As a protocol deviation, we included three studies that used
clinicopathological diagnostic criteria not specified in Types of
participants (Badrising 2002; Leff 1993; Walter 2000).
We identified three ongoing studies (one of which had three
associated trial registrations) from ClinicalTrials.gov and the
World Health Organization International Clinical Trials Registry Platform (EUCTR2007-004359-12-IT; NCT00001265;
NCT01423110). See Characteristics of ongoing studies.

‘Summary of findings’ table
We created a ‘Summary of findings’ table using the following outcomes.
1. Percentage change in muscle strength (using MMT or
QMT) from baseline at 6 months.
2. Percentage change from baseline in muscle strength (using
MMT or QMT) at 12 months.
3. Percentage change from baseline in muscle mass (by
whatever method, e.g. MRI) at 6 months.
4. Percentage change from baseline in handgrip strength at 6
months.
5. Percentage change from baseline in timed walk (e.g. 10metre or 6-minute walk) at 6 months.
6. Significant adverse events from the intervention.
We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias)
to assess the quality of a body of evidence (studies that contribute
data for the prespecified outcomes). We employed methods and
recommendations described in Chapter 12 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011), using
GRADEpro software (GRADEpro 2014). We justified all decisions to down- or upgrade the quality of studies using footnotes
and made comments to aid readers’ understanding of the review
where necessary. Three review authors (MR, KJ, and RB) completed this evidence grading, which all review authors checked and
agreed on.
Subgroup analysis and investigation of heterogeneity
We were unable to perform subgroup analysis to investigate treatment effects in particular groups of participants because the included studies provided insufficient detail about the different participant groups. We were unable to use meta-regression techniques
to investigate heterogeneity.
Sensitivity analysis
We would have completed a sensitivity analysis on the basis of
risk of bias and to further explore heterogeneity in the results if
sufficient data (trials) had been available.

RESULTS

Intravenous immunoglobulin versus placebo
Three trials compared IVIg with placebo (Dalakas 1997; Dalakas
2001; Walter 2000).
Dalakas 1997 block-randomised 22 participants fulfilling the diagnostic criteria according to Griggs 1995 either to placebo (consisting of dextrose in half-normal saline) or to 2 g/kg body weight
IVIg monthly for 3 months. After a washout period of at least
one month, the participants had the option of crossing over to the
alternative treatment for a further three months. Nineteen of the
participants were also being treated with prednisone or another
immunosuppressant (MTX, AZA) prior to the study; only three
participants continued with a low-to-moderate dose of prednisone
during the trial. Assessments were made at baseline and at the end
of each three-month period, with both investigators and participants blinded to the treatment intervention. The study authors
reported baseline mean total Medical Research Council (MRC)
scores to be comparable.
Walter 2000 block-randomised 22 participants (11 in each group)
fulfilling diagnostic criteria similar to Griggs 1995. Participants
were randomised to either placebo (1% human albumin in 2.5%
glucose) or to IVIg at 2 g/kg body weight given over two to five
days per month for six months, before crossing over to the other
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regimen for another six months. Nineteen of the participants had
received various drugs prior to the study, including corticosteroids,
AZA, and combined MTX and AZA. Six participants in each
group remained on a constant, pretreatment medication, with
nine receiving 2.5 mg to 15 mg daily corticosteroids and three
receiving 4 mg to 10 mg daily corticosteroids and 100 mg to 150
mg daily AZA. All participants in both groups received physiotherapy once or twice weekly. The trial was double blinded with
monthly outcome measurement from baseline to 12 months. Although the groups differed in baseline mean age (67 ± 12 years
in the IVIg-placebo group and 51 ± 11 years in the placebo-IVIg
group, the MRC sum scores and Neuromuscular Symptom and
Disability Functional Scores showed no statistically significant between-group differences at baseline.
Dalakas 2001 block-randomised 37 participants (according to the
flow chart in the study report) who fulfilled the diagnostic criteria
for IBM according to Griggs 1995 either to placebo (consisting of
dextrose in half-normal saline) or two daily doses of 1g/kg body
weight IVIg (2 g/kg bodyweight IVIg) monthly for three months.
In addition, all participants in both groups received prednisone
(tapered from 60 mg daily to 60 mg every other day). Assessments were made at baseline and at the end of each month of
treatment for three months, with investigators and participants
both blinded to intervention. At baseline, age and muscle strength
(QMT and MRC sum scores) were comparable between treatment
and placebo groups.

Interferon beta-1a versus placebo
Two trials compared the use of IFN beta-1a with placebo.
Muscle Study Group 2001 randomised 30 participants who had
definite or probable IBM according to the criteria of Griggs 1995
into a double-blinded, parallel-group study. Sample size was chosen “to provide 85% power to detect a difference in tolerability of
95% in the placebo group versus 50% in the IFN beta-1a group”.
The participants received either IFN beta-1a or a matching placebo
(lyophilised powder reconstituted with sterile saline). The dose of
IFN beta-1a was 15 µg/week initially and 30 µg/week from 4
weeks, administered by intramuscular injection once weekly for
24 weeks. Participants also received a 650 mg dose of paracetamol
at the time of injection and repeated six-hourly with a total of
four doses. Trialists made assessments at baseline and at 4, 12, and
24 weeks. Baseline characteristics suggested between-group similarity for age and average motor function; however, trial authors
acknowledge a predominance of men in the treatment group.
The second trial performed by the same group recruited 30 participants (Muscle Study Group 2004). The study design and outcome measures were consistent with Muscle Study Group 2001,
but the dosage of IFN beta-1a was increased to 60 µg/week. Assessments were reported at baseline and at 4, 12, and 24 weeks;
no primary outcome measure was specified. All reported baseline
characteristics suggested that the two treatment groups were clin-

ically similar. There was a predominance of men in the placebo
group.
Methotrexate versus placebo
One double-blinded trial randomised 44 participants to receive either MTX or an identical-looking placebo (Badrising 2002). Sample size was chosen “to detect a difference of 100 Newtons (N) in
mean [strength] changes or a clinically important stabilisation”.
Over a treatment period of 48 weeks, participants started on an
initial dose of 5 mg a week that increased by 5 mg every 6 weeks
up to 20 mg/week. To enhance blinding, the investigators reduced
the dose by 2.5 mg without explanation for three months, and restored doses to 20 mg/week thereafter. The average dose was 14.6
mg/week in those who completed the trial and 14.0 mg/week in
all treated participants. Forty-two participants had a diagnosis of
definite IBM and two a diagnosis of probable IBM, according to
the European Neuromuscular Centre (ENMC) diagnostic criteria for IBM (Verschuuren 1997), elements of which are similar
to those of Griggs 1995. Assessments were made at baseline, 22,
and 48 weeks or immediately after withdrawal. The baseline characteristics suggested between-group similarity. The study authors
performed both an intention-to-treat analysis, carrying forward
the last assessment, and a per protocol analysis of those who completed the study.
Combined immunosuppressive therapy:
methotrexate and anti-T lymphocyte
immunoglobulin versus methotrexate
Lindberg 2003 was an open, randomised trial of 11 participants
who fulfilled the morphological diagnostic criteria for IBM according to Griggs 1995. This trial compared 12 months’ treatment with oral MTX 7.5 mg/week (MTX group, n = 5) with 12
months’ MTX treatment preceded by 7 days of intravenous antiT lymphocyte immunoglobulin treatment (MTX + ATG group,
n = 6). ATG doses were fixed for the first two days (5 mg/kg and
4 mg/kg body weight, respectively) and varied thereafter to keep
the T lymphocyte counts between 50 x 106 /L and 150 x 106 /L.
The total amount of ATG given over seven days varied between
24.8 mg/kg and 30.2 mg/kg body weight. Five participants in the
MTX + ATG group and four participants in the MTX group also
took prednisone (10 mg to 30 mg every second day) during the
trial. Participants received methylprednisolone (125 mg injection)
before the first ATG infusion. Assessments were made 2 months
before commencement of treatment and at 0, 2, 4, 6, 9, and 12
months of treatment. Mean between-group muscle strength was
reported to be nearly equal at baseline.
Combined immunosuppressive therapy:
methotrexate and azathioprine versus methotrexate
(plus leucovorin)
Leff 1993 was an open, randomised trial of 11 participants who
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were diagnosed as having definite myositis by the Bohan and Peters’
criteria (Bohan 1975), together with light microscopic changes
consistent with biopsy-proven IBM.
The trial authors compared six months of intravenous MTX with
a combination treatment of oral azathioprine and MTX (AZA +
MTX). For the MTX regimen, the investigators infused 0.5 g/m2
intravenously over one hour every two weeks; participants on intravenous MTX also received oral doses of 50 mg/m2 leucovorin rescue. Oral doses of AZA and MTX began at 50 mg/day and 7.5 mg/
week, respectively, and gradually increased to a maximum of 150
mg/day and 25 mg/week, respectively, over the course of the first
12 weeks unless adverse events occurred. In addition, both treatment groups received prednisone, which was tapered to a small,
alternate-day dose of 0.25 mg/kg after one month. Participants
only crossed over regimens if worsening or stabilisation occurred
after six months of drug therapy. If improvement occurred after
the first six months, the participants continued prednisolone and
discontinued the trial therapy; such participants were kept under
observation, and only when worsening occurred did they begin
the other therapeutic regimen. The trial authors defined change
in clinical status by categorical changes in MMT and activities of
daily living (ADL) between the start and end of treatment. The
trial authors did not report whether participants’ baseline characteristics were similar.
Oxandrolone versus placebo
One trial compared oxandrolone, an anabolic steroid (a synthetic
androgen), with placebo (Rutkove 2002). This double-blinded
study randomised participants to 20 mg/day oxandrolone orally
(10 mg twice daily) (n = 10) or placebo (n = 9) for 12 weeks. After
a washout period of two to four months, the groups crossed over
to the alternate intervention for another 12 weeks. All participants
fulfilled the Griggs 1995 criteria for definite IBM. Assessments
were performed at baseline, at the end of the first intervention pe-

riod, at the end of the washout period, and at the end of the second
12-week intervention period (with additional serologic evaluation
at 6 weeks of each treatment). Only 13 of the 19 participants completed both periods of the study, although the changes reported
on oxandrolone were based on the 15 participants who completed
active treatment, and the changes reported on placebo were based
on the 14 participants who completed a placebo period. Baseline
median muscle strength (whole-body maximal voluntary isometric contraction testing and MMT scores) were significantly higher
in the group receiving placebo for the first study period (P = 0.03
and P = 0.008, respectively).
Arimoclomol versus placebo
Machado 2013 compared the safety and tolerability of arimoclomol with placebo in participants who fulfilled the diagnostic criteria for IBM according to Griggs 1995. This double-blinded trial
randomised one group to 100 mg three times daily and the other to
placebo for four months, with an eight-month blinded follow-up
phase. Available data were insufficient to determine the betweengroup similarity in baseline characteristics.

Risk of bias in included studies
We have reported ‘Risk of bias’ assessments for each included study
in Characteristics of included studies. Figure 1 summarises review
authors’ assessments for each ‘Risk of bias’ domain for all trials.
The overall risk of bias in the included studies was unclear in 6
of the 10 trials. The review authors evaluated one trial of MTX
as at low risk of bias (Badrising 2002). We judged three other
trials to be at high risk of bias: two open studies of multi-agent
treatment, Leff 1993 and Lindberg 2003, and Dalakas 1997, due
to incomplete outcome data, selective reporting, and breaking of
randomisation by elective cross-over.
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Figure 1. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study. Red (-) = high risk of bias, yellow (?) = unclear risk of bias and green (+) = low risk of bias.
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Insufficient information on blinding procedures was a common
source of unclear risk of bias; this finding was particularly important because the primary outcome was a measure of muscle
strength performance, likely to be influenced by a lack of blinding. Most studies also did not clearly demonstrate minimisation
of the potentially confounding effects of previous or concurrent
treatments.

Effects of interventions
See: Summary of findings for the main comparison Intravenous
immunoglobulin versus placebo for inclusion body myositis;
Summary of findings 2 Interferon beta-1a compared to placebo
for inclusion body myositis; Summary of findings 3 Methotrexate
compared to placebo for inclusion body myositis; Summary of
findings 4 Methotrexate and anti-T lymphocyte immunoglobulin
compared to methotrexate for inclusion body myositis; Summary
of findings 5 Methotrexate and azathioprine compared to
methotrexate (plus leucovorin) for inclusion body myositis;
Summary of findings 6 Oxandrolone compared to placebo for
inclusion body myositis
Intravenous immunoglobulin versus placebo
Three studies contributed data for this comparison (Dalakas 1997;
Dalakas 2001; Walter 2000).

Percentage change from baseline in muscle strength at 6
months

In Dalakas 1997 (19 analysed participants), the investigators assessed muscle strength change after three months of the intervention (cross-over study). The paper provided no statistical comparison between muscle strength in the IVIg and placebo groups at
baseline. Since participants had the option to cross over, only the
first period of the trial was randomised. We considered rescaling
trial data (0 to 10 scale; maximum sum score = 200) to estimate
the percentage change in muscle strength at six months despite an
assumption of linear change. However, we were not able to perform secondary analysis because no standard deviation (SD) values
were given. Primary data were not available for re-analysis, and we
could not accurately regenerate primary data from the graphs and
tables. At three months, trial authors found a non-significant gain
in mean MRC points with IVIg and a non-significant loss with
placebo. The mean change in the IVIg group was 4.2 MRC points
(range -16 to 39.8), whereas the mean change in the placebo group
was -2.7 MRC points (range -10 to 8). Trial authors reported “the
effect of IVIg did not differ significantly compared with placebo
in overall muscle strength” using a per protocol analysis.
In Dalakas 2001 (36 analysed participants; 19 in treatment group),
trialists assessed muscle strength change following three months of
the intervention (parallel-group study). We considered whether to

rescale trial data (0 to 10 scale) to estimate the percentage change
in muscle strength at six months. However, the maximum sum
score was unclear, as the study authors described 12 muscle group
actions but reported 13 muscle groups as assessed. Also, they reported muscle strength change from baseline separately for upper
and lower extremities, despite the primary outcome measure being
total-body MRC sum scores. At three months, trial authors found
no significant difference in mean muscle strength scores with IVIg
compared with placebo. Trial authors concluded “the lack of improvement in strength, the primary endpoint of our study, was
disappointing” based on a per protocol analysis. We intended to
pool the data for upper and lower extremities, but primary data
were unavailable for secondary analysis.
In Walter 2000 (20 analysed participants), the investigators assessed muscle strength change following six months of the intervention (cross-over study). They reported comparable baseline
muscle strength between IVIg and placebo groups based on MRC
sum scores (P = 0.49). In the first period of the trial, there was a
mean increase of 2.5 MRC points (0 to 6 scale; maximum sum
score = 180) with IVIg from a baseline of 137.4 (± 28.3) to 139.9
(± 30.6); in the placebo group there was a mean increase of 4 MRC
points from a baseline of 141.5 (± 33.8) to 145.5 (± 26.6) points.
In the second period of intervention following cross-over, there
was a mean increase of 4.5 MRC points, from 145.5 (± 26.6) to
150 (± 25.3) with IVIg and 6.8 MRC points with placebo, from
139.9 (±30.6) to 146.7 (± 28.1). The trial publication did not
clearly state whether the figures in parentheses are SD. Trial authors also provided the overall comparative data for IVIg-placebo
versus placebo-IVIg groups, although this does not measure IVIg
efficacy. Trial authors reported “there were no significant changes
in MRC scales during IVIg treatment” based on a per protocol
analysis of efficacy data. We intended to pool the data for percentage change in muscle strength with IVIg versus placebo, but
primary data were unavailable for secondary analysis.

Percentage change from baseline in muscle strength at 12
months

No available data.

Percentage change from baseline in handgrip at 6 months

No available data.

Percentage change from baseline in muscle mass at 6
months

No available data.
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Percentage change from baseline in timed walk at 6 months

No available data.

Significant adverse events from the intervention

In Dalakas 1997, two participants dropped out of the study before
completing the first period, and a third completed the first period
but refused to continue for reasons not stated. It is not clear if these
dropouts were from the treatment or placebo group. In Dalakas
2001, there was one dropout from the placebo group due to death
following a heart attack after the first infusion. In Walter 2000, the
trial authors recorded two dropouts, but did not provide reasons
for their discontinuation.
Dalakas 1997 and Dalakas 2001 did not report adverse events experienced by participants in sufficient detail for the review authors
to analyse the data. In Dalakas 1997, trial authors reported that
there were no serious side effects; some participants experienced
a mild headache, but without specification of the intervention
group. In Dalakas 2001, trial authors again noted no serious side
effects in the IVIg-randomised participants. Walter 2000 reported
no serious adverse events during the trial, although two participants had headaches with raised body temperature (38°C), and
two participants developed allergic exanthema of the skin.
Interferon beta-1a versus placebo
Two studies contributed data for this comparison (Muscle Study
Group 2001; Muscle Study Group 2004).

Percentage change from baseline in muscle strength at 6
months

In Muscle Study Group 2001 (29 analysed participants but 30 reported with an intention-to-treat (ITT) principle; 14 in treatment
group), investigators assessed the muscle strength change following
24 weeks of the intervention (parallel-group study). They tested

a total of 34 muscle groups, and the text suggested a maximum
MRC sum score of 170 (based on an MRC scale of 0 to 5). Trial
authors generated a ‘composite’ score, which is defined in relation
to QMT strength scores as “the average number of SD units from
predicted normal strength, given age, gender and height of the
subject”. The mean MMT changes of 0.03 (SD 0.16) increment
with placebo and 0.06 (SD 0.15) decline with IFN beta-1a appear
to be consistent with a non-significant change in mean number of
SD units plus SD, rather than mean muscle strength scores plus
SD. The results were in favour of placebo (MD -0.09, 95% CI 0.20 to 0.02) based on an ITT principle with no computation of
missing data. However, the formulation of the composite MMT
score was not clear. We intended to ascertain the percentage change
in muscle strength for IFN beta-1a versus placebo, but primary
data were unavailable for secondary analysis.
In Muscle Study Group 2004 (28 analysed participants including
carry-forward of 1 participant’s data and no computation of missing data from 2 participants; 15 in treatment group), the trialists
assessed muscle strength change similarly following 24 weeks of
the intervention (parallel-group study). The dosage of IFN beta1a was double that used in the earlier trial, but study methodology
was otherwise consistent. The mean MMT decreases of 0.08 (SD
0.21) with placebo and 0.08 (SD 0.22) with IFN beta-1a again
appeared to be consistent with a non-significant change in mean
number of SD units plus SD, although this was not clearly stated.
The results were neither in favour of placebo nor IFN beta-1a
(MD 0.00, 95% CI -0.16 to 0.16).
As we were unable to ascertain percentage change in muscle
strength, we decided to complete a pooled analysis of data from
the two trials for change in normalised muscle strength sum scores.
Overall, there was no significant benefit of IFN beta-1a over
placebo; the combined data (58 participants) produced an MD
of -0.06 (95% CI -0.15 to 0.03) in favour of placebo, but nonsignificant (Analysis 1.1; Figure 2). The result was not sensitive to
the use of a fixed-effect versus a random-effects analysis.
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Figure 2. Forest plot of comparison: 1 Interferon beta-1a versus placebo, outcome: 1.1 Normalised change
in muscle strength over baseline at 6 months.

Percentage change from baseline in muscle strength at 12
months

No available data.

Percentage change from baseline in handgrip at 6 months

Data were unavailable for secondary analysis of handgrip strength;
no baseline data were provided to estimate percentage change in
handgrip strength based on the mean change in each participant.
However, the mean change in grip strength scores was reported: 0.72 kg (SD 1.99) with IFN beta-1a and -0.72 kg (SD 1.46) with
placebo (MD -0.16 kg, 95% CI -1.55 to 1.22) for Muscle Study
Group 2001. Muscle Study Group 2004 reported a change in grip
strength of +0.23 kg (SD 1.66) with IFN beta-1a and -1.45 kg
(SD 1.44) with placebo (MD 1.84 kg, 95% CI 0.46 to 3.21) in
favour of IFN beta-1a. In the absence of normalised or percentage
change data, we did not perform pooled analysis of the data from
these two trials.

Percentage change from baseline in muscle mass at 6
months

Muscle Study Group 2001 and Muscle Study Group 2004 measured lean mass as a surrogate for muscle mass.
In Muscle Study Group 2001, there was an increase in lean mass
of 0.1% with IFN beta-1a and a decrease of 0.85% with placebo.

The mean reported change was +0.04 kg (SD 1.10) from a baseline
of 40.1 kg (SD 7.5) with IFN beta-1a, and -0.34 kg (SD 1.96)
from a baseline of 39.8 kg (SD 9.4) with placebo (MD 0.64 kg,
95% CI -0.71 to 1.99, with MD adjusted for investigator effects
in an analysis-of-variance model). When calculated by percentage
change, the MD was 0.95%, 95% CI -1.86 to 3.76.
In Muscle Study Group 2004, there was a decrease in lean mass
with IFN beta-1a (-2.18%) and placebo (-1.77%). There was a
decrease of 0.94 kg (SD 1.32) from a baseline of 43.2 kg (SD 10.2)
in the IFN beta-1a group, and a decrease of 0.82 kg (SD 1.79)
from a baseline of 46.3 kg (SD 9.9) in the placebo group (MD 0.10, 95% CI -1.40 to -1.19, with MD adjusted as previously).
When calculated by percentage change, the MD was -0.41%, 95%
CI -3.02 to 2.20.
Overall, the positive gain in lean mass was negligible in the first
study relative to the large SD values and an undefined dual energy
X-ray absorptiometry precision error; there was no positive gain
of lean mass in the second study. Subsequently, IFN beta-1a did
not appear to influence lean mass after six months of treatment,
irrespective of the therapeutic dose. The combined percentage
change data from these 2 trials (58 participants) produced an MD
of 0.22% (95% CI -1.69 to 2.13) in favour of IFN beta-1a; the
CI includes the possibility of an effect favouring either IFN beta1a or placebo (Analysis 1.2; Figure 3). The result was not sensitive
to the use of a fixed-effect versus a random-effects analysis.
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Figure 3. Forest plot of comparison: 1 Interferon beta-1a versus placebo, outcome: 1.2 Percentage change
over baseline in muscle mass at 6 months.

Percentage change from baseline in timed walk at 6 months

Methotrexate versus placebo

No available data.

Significant adverse events from the intervention

In Muscle Study Group 2001, 1 participant from the IFN beta-1a
group withdrew from the study owing to death post-surgery for
colon cancer; although 29 people completed the trial, the study authors based subsequent analysis on all 30 participants (16 placebo,
14 IFN beta-1a), carrying forward the results of the deceased. In
Muscle Study Group 2004, three participants dropped out of the
trial, two from the IFN beta-1a group and one from the placebo
group. The analyses carried forward data from one of the dropouts
in the IFN beta-1a group to the endpoint of the study. The reason
given for one participant dropping out of the IFN beta-1a group
was post-injection flu-like reaction; the reason for the other IFN
beta-1a group dropout is not clear from the report.
Adverse events reported with IFN beta-1a included one death postintervention with cause unlikely to be related to medication, flulike symptoms, arthralgia/myalgias, skin rash, injection site reaction, diarrhoea, headache, depression, chills/fever, and abdominal
pain or classified as other/unspecified. Trial authors reported numbers of participants experiencing each type of adverse event and
mean numbers of adverse events per participant. Muscle Study
Group 2001 recorded a mean of 2.65 (no SD provided) participant-reported adverse events with IFN beta-1a compared with
2.25 (no SD) in the placebo group. In Muscle Study Group 2004,
the trial authors recorded a mean of 4.00 (SD 2.83) participantreported adverse events with IFN beta-1a, compared with 2.36
(SD 1.98) with placebo. Only Muscle Study Group 2004 reported
the proportion of participants experiencing any type of adverse
event following intervention: 79% of participants reported adverse
events with placebo, and 81% with IFN beta-1a.

Percentage change from baseline in muscle strength at 6
months

One study contributed data for this comparison (Badrising 2002).
No six-month data were available, although ITT and per protocol
analyses shown in graphs indicated declines in compound QMT
at 22 weeks in both MTX and placebo groups.

Percentage change from baseline in muscle strength at 12
months

Badrising 2002 (44 analysed participants; 21 in the treatment
group using ITT analysis) reported mean changes in muscle
strength sum scores using percentages, thus we presented the results as reported by trial authors. For the primary outcome measure of the trial, mean QMT sum scores declined in both groups
by 48 weeks (-0.2% in MTX and -3.4% in placebo) (MD 3.2%,
95% CI -2.5% to 9.1%). By limiting analysis to only those participants who fully completed the study (per protocol analysis),
the trial authors found 0.9% improvement with MTX compared
to a decline of 2.7% with placebo (MD 3.6%, 95% CI -3.3% to
10.7% in favour of placebo).
Mean MMT sum scores also declined in MTX and placebo groups:
-0.5% for MTX and -2.0% for placebo (MD 1.5%, 95% CI 1.0% to 3.9%). Using the per protocol analysis, MMT sum score
changes were -2.2% for MTX and -3.8% for placebo (MD 1.6%,
95% CI -2.3% to 5.4%).

Percentage change from baseline in handgrip at 6 months

No available data.
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Percentage change from baseline in muscle mass at 6
months

Percentage change from baseline in muscle mass at 6
months

No available data.

No available data.

Percentage change from baseline in timed walk at 6 months

Percentage change from baseline in timed walk at 6 months

No available data.

No available data.

Significant adverse events from the intervention

Eight of the 21 participants in the MTX group dropped out,
compared with 1 of 23 in the placebo group (risk ratio (RR) 8.76,
95% CI 1.19 to 64.28, Analysis 2.1). The significantly higher
dropout rate reported with MTX was due to nausea (n = 3), hair
loss (n = 2), arthralgia (n = 2), and progressive muscle weakness
(n = 1). One participant on placebo treatment discontinued trial
medication because of progressive muscle weakness. Both cases
of dropout for progressive muscle weakness could have been the
result of disease progression, but trial authors classified them as
adverse events. Trial authors also reported that four participants in
the MTX group and one participant in the placebo group required
dose reductions, although it is not clear whether these were the
same people who discontinued with the trial.

Combined immunosuppressive therapy:
methotrexate and anti-T lymphocyte
immunoglobulin versus methotrexate
One study contributed data for this comparison (Lindberg 2003).

Percentage change from baseline in muscle strength at 6
months

Significant adverse events from the intervention

Ten participants completed the trial, but the trial authors based
the analysis on 11 participants by carrying forward the data taken
from the last assessment of the 1 person who dropped out. The
use of ATG in this trial was not complicated by any serum sickness or anaphylaxis. However, one participant in the MTX group
developed severe pneumonia after 118 days of treatment and was
withdrawn from the study.

Combined immunosuppressive therapy:
methotrexate and azathioprine versus methotrexate
(plus leucovorin)
One study contributed data for this comparison (Leff 1993). The
trial authors measured change in muscle strength based on MMT
but presented results categorically (improved, stabilised, or worse),
which prevented any data extraction.

Percentage change from baseline in muscle strength at 6
months

No available data.

No available data.
Percentage change from baseline in muscle strength at 12
months
Percentage change from baseline in muscle strength at 12
months

At 12 months, the MTX + ATG group showed a change of 1.4%
(SD 9.8%) in compound QMT compared with -11.1% (SD
7.2%) in the MTX group (P = 0.021). In the MTX + ATG group,
mean strength increased from 90.3 N (SD 15.3) to 91.6 N (SD
18.2), as compared to the MTX group, in which there was a decrease from 78.4 N (SD 33.3) to 71.4 N (SD 34.5). The MD was
12.50% (95% CI 2.43 to 22.57) in favour of MTX (Analysis 3.1).

No available data.

Percentage change from baseline in handgrip at 6 months

No available data.

Percentage change from baseline in muscle mass at 6
months

No available data.
Percentage change from baseline in handgrip at 6 months

No available data. The review authors opted not to rescale trial
data from 12 to 6 months due to the uncertainty of assuming a
linear change between these time points.

Percentage change from baseline in timed walk at 6 months

No available data.
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Significant adverse events from the intervention

Two of 11 participants discontinued combined AZA and MTX
treatment due to side effects that were described as transient, reversible, and mainly gastrointestinal; these participants both underwent cholecystectomies for acute cholecystitis and were unable
to resume drug treatment. A third participant did not cross over
to MTX (plus leucovorin) due to pneumonitis. Another complication reported during the trial was a flareup of pre-existing
gout in one participant during MTX (plus leucovorin) treatment.
Trial authors reported that most participants received the full six
months of each regimen. Insufficient data were available to give
actual numbers of participants from each group who experienced
significant adverse events.

Percentage change from baseline in muscle strength at 6
months

Insufficient data.

Percentage change from baseline in muscle strength at 12
months

Insufficient data.

Percentage change from baseline in handgrip at 6 months

No available data.

Percentage change from baseline in muscle mass at 6
months

Oxandrolone versus placebo
One study contributed data for this comparison (Rutkove 2002).
This was a cross-over trial that reported the effects of 12 weeks’
treatment with oxandrolone versus placebo. Overall changes were
reported at the end of the trial for 15 participants who completed
the oxandrolone phase and 14 participants who completed the
placebo phase. The trial authors reported median values and interquartile ranges “because of concerns about the normality of the
data”. The trial authors expressed results as GEE (generalised estimating equation) estimates and standard errors, with the result
that the available data were insufficient to calculate percentage
change in outcome measures.

Insufficient data.
The analyses only excluded those participants who dropped out
prior to completion of the first treatment period.
Arimoclomol versus placebo
One trial investigated the use of arimoclomol for treating IBM
(Machado 2013). However, only the abstract was available at the
time of this review. In the pilot study, 16 participants used arimoclomol (100 mg 3 times daily) and 8 participants received a
placebo for 4 months. The abstract did not report numerical data
suitable for inclusion in this review.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]

Interferon beta-1a (IFN beta-1a) compared to placebo for inclusion body myositis
Patient or population: people with inclusion body myositis
Settings:
Intervention: IFN beta-1a
Comparison: placebo
Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of participants
(studies)

Quality of the evidence
(GRADE)

Assumed risk

Corresponding risk

Placebo

IFN beta-1a

The mean changes in normalised muscle strength
in the control groups was
-0.03 and -0.08

The mean change in nor- malised muscle strength
in the intervention groups
was
0.06 lower
(0.15 lower to 0.03
higher)

58
(2 studies)

⊕⊕⊕
moderate1

Change
in
muscle strength at 12 months
(%) - not measured

-

-

-

Change in muscle mass The mean change in musat 6 months (%)
cle mass (%) in the control groups was -0.85 and
-1.77.

The mean change in mus- cle mass (%) in the intervention groups was
0.22 higher (1.69 lower
to 2.13 higher)

58
(2 studies)

⊕⊕⊕
moderate1

Change
in
muscle
strength at 6 months
(normalised MMT score
- see Characteristics of
Studies table)

-

Comments

-
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Change in handgrip Not estimable
strength at 6 months (%)

Not estimable

Not estimable

58 (2 studies)

See comment

Baseline measurements
were not reported, so %
change was not calculable. There was a nonsignificant difference in
handgrip strength (kg) between IFN beta-1a and
placebo in 1 trial (MD -0.
16, 95% CI -1.55 to 1.22)
. In the other the MD was
1.84 kg with a 95% CI of
0.46 to 3.21 in favour of
IFN beta-1a

Change in timed walk at 6 months (%)
e.g. 10-metre or 6-minute
walk test at 6 months not measured

-

-

-

-

-

Significant
events

Not estimable

Not estimable

58 (2 studies)

See comment

Muscle Study Group
2001: treatment group
withdrawals = 1; placebo
group withdrawals = 0.
Muscle Study Group
2004: treatment group
withdrawals = 2; placebo
group withdrawals = 1

adverse Not estimable

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; MD: mean difference; MMT: manual muscle testing
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
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Very low quality: We are very uncertain about the estimate.
1

The CI includes the possibility of an effect favouring either IFN beta-1a or placebo when data from the two trials are combined.
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Methotrexate compared to placebo for inclusion body myositis
Patient or population: people with inclusion body myositis
Settings:
Intervention: methotrexate
Comparison: placebo
Outcomes

Illustrative comparative risks* (95% CI)

22

Relative effect
(95% CI)

No of Participants
(studies)

Quality of the evidence
(GRADE)

Comments

Not estimable

44 (1 study)

See comment

Data collected at 12
months only

Change
in
muscle The mean change in mus- The mean change in mus- strength at 12 months cle strength (%) in the cle strength (%) in the in(%) - MMT
control group was -2.0% tervention group was
1.5% higher
(1.0 lower to 3.9 higher)

44 (1 study)

⊕⊕
moderate1

MD in mean change
based on intention-totreat data. Per protocol:
MD 1.6%, 95% CI -2.3 to
5.4. This study was assessed as having a low
overall risk of bias

Change in muscle mass at 6 months (%) - not
measured

-

-

-

-

-

Change in handgrip strength at 6 months (%)
- not measured

-

-

-

-

-

Change in timed walk at 6 months (%)
e.g. 10-metre or 6-minute
walk test at 6 months -

-

-

-

-

-

Assumed risk

Corresponding risk

Placebo

Methotrexate

Change
in
muscle Not estimable
strength at 6 months (%)

Not estimable
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not measured
Significant
events

adverse 43 per 1000

381 per 1000 (52 to RR 8.76 (1.19 to 64.28)
1000)

44 (1 study)

⊕⊕
moderate2

Badrising 2002: treatment group withdrawals
= 8/21; placebo group
withdrawals = 1/23

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; MMT: manual muscle testing; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1

2

Downgraded for imprecision. The single randomised controlled trial of methotrexate was insufficiently powered to exclude a possible
benefit from methotrexate.
Downgraded for imprecision.
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Methotrexate (MTX) and anti-T lymphocyte immunoglobulin (ATG) compared to MTX for inclusion body myositis
Patient or population: people with inclusion body myositis
Settings:
Intervention: methotrexate and anti-T lymphocyte immunoglobulin
Comparison: methotrexate
Outcomes

Illustrative comparative risks* (95% CI)

Assumed risk

Corresponding risk

MTX

MTX and ATG

Relative effect
(95% CI)

No of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Data collected at 12
months only

Change
in
muscle Not estimable
strength at 6 months (%)

Not estimable

Not estimable

11
(1 study)

See comment

Change
in
muscle The mean change in musstrength at 12 months cle strength (%) in the
(%) - QMT
control group was -11.
1%

The mean change in mus- Not estimable
cle strength (%) in the intervention groups was
12.50 higher
(2.43 to 22.57 higher)

11
(1 study)

⊕
very low1

Change in muscle mass at 12 months (%) - not
measured

-

-

-

-

-

Change in handgrip Not estimable
strength at 6 months (%)

Not estimable

Not estimable

11
(1 study)

See comment

Data collected at 12
months only; rescaling of
data not performed due
to uncertainty in the assumption of linear change
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Change in timed walk at 6 months (%)
e.g. 10-metre or 6-minute
walk test at 6 months not measured

-

-

-

-

-

Significant
events

Not estimable

Not estimable

11
(1 study)

See comment

Lindberg 2003: combined
ATG and MTX group withdrawals = 0; MTX group
withdrawals = 1

adverse Not estimable

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; MD: mean difference; QMT: quantitative muscle testing; RR: risk ratio
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1
2

Downgraded for study design: as an open-label study, there is a high risk of bias.
Downgraded twice for imprecision: 11 participants. The minimum clinically important difference is not known, and the MD has wide CI.
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Methotrexate (MTX) and azathioprine (AZA) compared to MTX (plus leucovorin) for inclusion body myositis
Patient or population: people with inclusion body myositis
Settings:
Intervention: methotrexate and azathioprine (plus leucovorin)
Comparison: methotrexate
Outcomes

Illustrative comparative risks* (95% CI)

Assumed risk

Corresponding risk

Methotrexate

Methotrexate and azathioprine

Relative effect
(95% CI)

No of Participants
(studies)

Quality of the evidence
(GRADE)

Comments

Change
in
muscle Not estimable
strength at 6 months (%)

Not estimable

Not estimable

11
(1 study)

See comment

Categorical change in
MMT only reported. This
study was graded as having a high risk of bias

Change
in
muscle strength at 12 months
(%) (using MMT or QMT)
at 12 months - not measured

-

-

-

-

-

Change in muscle mass at 6 months (%) - not
measured

-

-

-

-

-

Change in handgrip strength at 6 months (%)
- not measured

-

-

-

-

-
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Change in timed walk at 6 months (%)
e.g. 10-metre or 6-minute
walk test at 6 months not measured

-

-

-

-

-

Significant
events

Not estimable

Not estimable

11
(1 study)

See comment

Leff 1993: Combined AZA
and MTX = 3 withdrawals; MTX (plus leucovorin) = 0 withdrawals

adverse Not estimable

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; MMT: manual muscle testing; QMT: quantitative muscle testing
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
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Oxandrolone compared to placebo for inclusion body myositis
Patient or population: people with inclusion body myositis
Settings:
Intervention: oxandrolone
Comparison: placebo
Outcomes

Illustrative comparative risks* (95% CI)

Assumed risk

Corresponding risk

Placebo

Oxandrolone

Relative effect
(95% CI)

No of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Change
in
muscle Not estimable
strength at 6 months (%)

Not estimable

Not estimable

16 (1 study)

See comment

Data collected at 12
months only; re-scaling of
data not performed due
to uncertainty in the assumption of linear change.
There were also insufficient data to calculate percentage change in muscle
strength. This study was
graded as having an unclear risk of bias

Change
in
muscle strength at 12 months
(%) - not measured

-

-

-

-

-

Change in muscle mass Not estimable
at 6 months (%)

Not estimable

Not estimable

16 (1 study)

See comment

Data collected at 12
months only; rescaling of
data not performed due to
uncertainty in the assumption of linear change
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Change in handgrip strength at 6 months (%)
- not measured

-

-

-

-

-

Change in timed walk at 6 months (%)
e.g. 10-metre or 6-minute
walk test at 6 months not measured

-

-

-

-

-

Significant
events

Not estimable

Not estimable

Not estimable

See comment

Rutkove 2002: treatment
group withdrawals = 1;
placebo group withdrawals
=2

adverse Not estimable

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
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DISCUSSION
Intravenous immunoglobulin versus placebo
We planned to perform a meta-analysis of the IVIg trials using
data reported for our primary outcome, muscle strength, albeit at
different time points. However, none of the IVIg studies reported
data in a form that could be combined at 3, 6, or 12 months.
Dalakas 1997 presented change in MRC sum scores for participants at three months in graphical form; we did not feel confident
to accurately convert the graphical data to numerical values for
meta-analysis. Additionally, we expected the need to extrapolate
three-month data to six months to amplify any existing inaccuracies. In order to perform our analysis, we would have needed to
rescale the original three-month trial data to six months, assuming
a linear rate of change in strength over time. Dalakas 2001 provided summary data for upper and lower limbs, but calculation of
a percentage change from these summary scores and extrapolation
to six months would again be subject to large assumptions in terms
of the effect size. The Walter 2000 cross-over trial similarly did
not provide data in a form suitable for meta-analysis.
Walter 2000 included 2 groups of 11 participants of different mean
ages (67 years and 51 years); in theory, the cross-over design of
the trial should negate any baseline differences seen between the
two groups. However, we were unable to perform subgroup analysis with respect to age because of insufficient data. Subsequently,
we cannot rule out the influence of faster disease progression in
the older subgroup in relation to sarcopenia and enhanced mitochondrial dysfunction, as proposed previously (Dalakas 2001;
Santorelli 1996). Exploring the relationship between inflammation, mitochondrial dysfunction, and muscle atrophy and determining the rate of IBM progression could be essential for understanding any clinically relevant change with treatment (Rygiel
2014); additionally, we may need to consider the sexual dimorphic
effect of ageing in relation to muscle protein synthesis in IBM, as
postulated in the study of older adults (Smith 2012). While an
ageing effect on our reviewed outcomes cannot be confirmed, the
small, non-significant improvements in muscle strength with both
IVIg and placebo may indicate a general learning effect in strength
measurement as a proxy measure for disease progression; Neuromuscular Symptom and Disability Functional Score changes
showed statistically significant improvement with IVIg only. We
planned to perform subgroup meta-analyses for factors such as age
and carry-over effect, but insufficient data were available.
In terms of the intervention, Dalakas 2001, unlike the other two
trials, provided the IVIg and non-IVIg groups with equal doses of
prednisone. The supplementation with prednisone was provided
on the basis that the combination of steroid with IVIg might have
a synergistic effect in improving muscle strength, based on studies
in dermatomyositis and Guillain-Barré syndrome (Dalakas 1993;
Dutch GBS 1994). However, unlike for IBM, for dermatomyositis
and Guillain-Barré syndrome, IVIg alone is known to be effective.
For the purposes of meta-analysis, we would have to assume that

prednisone did not contribute any effect for either the IVIg or
non-IVIg treatment group.
In terms of study design, the three trials used two different MRC
scales, and they did not assess the same muscle groups or muscle
group actions. Dalakas 1997 involved elective cross-over in the
second phase of the trial, such that we could consider only the
first phase of intervention for meta-analysis (Elbourne 2002). The
inconsistency in methodology between trials is particularly important because IBM affects different muscles to a variable extent. As
a result of the variable muscle involvement in IBM, IVIg might
be beneficial for some muscles more than others at any given time
point in the disease.
When summarising our findings, we assessed the quality of evidence for the effects of IVIg on muscle strength at six months as
very low due to selective reporting and other issues of trial design
(high risk of bias in one of the trials and an unclear overall risk of
bias in the other two trials).
In conclusion, while marginal increments in muscle strength were
identified in two of three trials of IVIg (Dalakas 1997; Walter
2000), we could not determine an overall effect of IVIg versus
placebo due to inconsistencies in trial methodology and reporting
(see Summary of findings for the main comparison).
None of the IVIg trials included a statistical analysis of the incidence of significant adverse events with intervention to facilitate
full evaluation of treatment effect. According to Meyler’s Side Effects of Drugs (Chalker 2000; Dukes 2000), current Ig preparations
cause about 3% to 4% of people to experience adverse reactions.
Other adverse events associated with IVIg include mild influenzalike illness, sweating, hypotension, chills, fever, nausea, and vasomotor reactions. More serious adverse effects include anaphylactic
reactions; however, these are very rare and may occur in as few as 1
in 6000 people (Aronson 2006). Stroke and myocardial infarction
have been reported after high-dose IVIg, as a result of increased
plasma viscosity. At high doses, neutropenia and disseminated intravascular coagulation have also been reported, and very rarely,
acute renal failure (Aronson 2006). Walter 2000 reported some
participants developing headache or raised body temperature, and
two participants developed an allergic reaction.

Interferon beta-1a versus placebo
Neither of the IFN beta-1a studies showed a significantly greater
benefit with IFN beta-1a over placebo. We were able to perform
a meta-analysis of parallel-group trials comparing different doses
of IFN beta-1a with placebo. The standardised trial procedures
and reporting across both trials made pooling of data from Muscle
Study Group 2001 and Muscle Study Group 2004 possible. The
pooled analysis for normalised muscle strength change from baseline produced a MD in compound MMT in favour of placebo
(moderate-quality evidence), but with CIs including the possibility of an effect in either direction (Analysis 1.1; Figure 2; Summary
of findings 2). The forest plot for lean mass, as surrogate for mus-
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cle mass (Figure 3), also did not show an effect in favour of IFN
beta-1a (moderate-quality evidence).
Despite some reported improvement in grip strength with IFN
beta-1a treatment, we could not assess the quality of this evidence
because the available data were incomplete.
Neither of the IFN beta-1a trials included a statistical analysis of
the incidence of significant adverse events to facilitate full evaluation of the treatment effect. Among the participants who took
30 µg doses of IFN beta-1a, 84% reported adverse events (Muscle
Study Group 2001); this figure was approximately 81% in participants who took 60 µg doses of IFN beta-1a (Muscle Study Group
2004). Flu-like reactions following injection were the most commonly specified complaint with high-dose treatment, while diarrhoea was the most commonly specified adverse event with lowdose treatment (Muscle Study Group 2001; Muscle Study Group
2004). Rarer adverse events associated with IFN beta-1a can include mood and personality changes, suicide attempts, hepatitis,
and thyroid dysfunction (Aronson 2006). Such an adverse event
profile and the large percentage of users experiencing more minor
adverse events may give rise to problems with compliance over
a longer period. However, despite the high frequency of adverse
events seen in these two trials, none was assessed as significant
enough to require dose reduction (Muscle Study Group 2001;
Muscle Study Group 2004).

its effects when combined with MTX. Adverse effects known to be
associated with ATG include “leukopenia and thrombocytopenia,
fever, arthralgia, rash, urticaria, hepatotoxicity, hyperglycaemia,
hypertension, and diarrhoea” (Aronson 2006). Serum sickness can
also occur later. However, none of these potential adverse effects
was reported in the trial; only a single case of pneumonia was reported.
In the only trial that looked at AZA and MTX in combination
(Leff 1993), we could obtain no quantitative data (see Summary of
findings 5). Similar to Lindberg 2003, this trial was open label and
had a small number of participants (very low-quality evidence).
As a combination therapy, there was a risk of exposure to the
effects of both drugs in the combination. Adverse events on the
regimen that included AZA were gastrointestinal symptoms, acute
cholecystitis, and a case of pneumonitis. In the MTX alone group,
the authors reported only a flareup of pre-existing gout; other
adverse events known to occur with AZA alone include fever,
nausea, leukopenia, thrombocytopenia, and anaemia (Aronson
2006). Neither Lindberg 2003 nor Leff 1993 provided a statistical
analysis of the incidence of significant adverse events with the
intervention to facilitate a full evaluation of the treatment effect.

Oxandrolone versus placebo
Methotrexate versus placebo
A single RCT provided moderate-quality evidence of no significant
effect of MTX on muscle strength at 12 months; the trial was
insufficiently powered to exclude a possible benefit from MTX (see
Summary of findings 3). Approximately 38% of participants who
were on MTX reported adverse events (Analysis 2.1), and there
was a statistically significant dropout rate in the MTX treatment
group (moderate-quality evidence). A larger or longer trial of MTX
could be problematic in terms of compliance (Badrising 2002).
The most common adverse events caused by MTX are nausea,
vomiting, alopecia, oral mucositis, or effects of myelosuppression
(Aronson 2006). While there are pharmacological agents to reduce
or alleviate common adverse events, polypharmacy may also affect
compliance.

Combination therapy in the treatment of IBM
The benefit of combination therapy with MTX and ATG,
Lindberg 2003, or MTX and AZA, Leff 1993, remains unclear
in the treatment of IBM. Combined MTX and ATG appeared to
show some benefit, but the evidence, based on a small, open-label
trial, is very low quality and should be interpreted with caution
(see Summary of findings 4) (Lindberg 2003). Aside from risk of
bias issues, any positive effect of ATG combined with MTX versus
MTX alone could either be due to the effects of ATG alone or to

In comparing oxandrolone with placebo, the trial authors highlighted that small numbers of participants and a relatively short
trial duration restricted the interpretation of results (Rutkove
2002). The trial authors also considered that between-group differences in baseline characteristics may have had some confounding effects. The trial authors reported a close-to-significant treatment effect for improving whole body strength with oxandrolone
at 12 weeks. However, we noted that the methods of analysis (generalised estimating equation) were unusual for this trial design,
and the power of the test for carry-over effects was low. Taking
into account these and the other study limitations, results should
be interpreted with caution (very low-quality evidence).
In terms of adverse events, anabolic steroids have some androgenic
activity that can give rise to acne and other signs of virilisation
and may affect lipoprotein profiles. As the associated androgenic
activity is weak, these adverse events are not common. However,
gynaecomastia has occurred with the long-term use of anabolic
steroids as a growth promoter in boys (Aronson 2006). Withdrawal
of high doses of anabolic steroids can give rise to menopause-like
symptoms (Chalker 2000; Dukes 2000). Rutkove 2002 reported
no significant adverse events, which was perhaps related to the low
doses used over a relative short period of time but, as with all other
analysed trials, the investigators included no definition of what
constituted an adverse event in order to evaluate treatment effect.
If anabolic steroids are associated with few or no significant adverse
events in practice, possible therapeutic potential might justify further trials to explore their use in treating IBM. Conversely, more
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adverse events and issues with compliance may be anticipated in
a longer trial of anabolic steroids.

Arimoclomol versus placebo
At the time of review, we did not attempt to evaluate the effects
of arimoclomol for treating IBM because the relevant data were
not available for systematic review. The trial was only available in
abstract (Machado 2013), and it was powered to assess safety and
tolerability, not treatment effect.

The lessons from these trials
This systematic review of treatment for IBM identified nine
analysable RCTs and one RCT published in an abstract only. In
terms of determining a treatment effect, only 2 of the included
trials reported power calculations, and we evaluated all 10 trials as
underpowered to detect a statistically significant effect. One trial
that included power calculations was primarily a safety and tolerability study, rather than an efficacy study (Muscle Study Group
2001). The other trial indicated multiple reasons for the lowerthan-expected power for their study, including rate of decline in
the placebo group; variability in QMT strength measures; and a
higher-than-expected participant dropout rate (Badrising 2002).
The largest included RCT had only 22 participants in the treatment group (Walter 2000). The largest analysed treatment group
included only 21 participants, using an intention-to-treat analysis
(Badrising 2002), and 20 participants with a per protocol analysis of the primary outcome measure (Walter 2000). Rose 2001
calculated that each group of a placebo-controlled trial needed 94
participantsto have 90% power to detect a 4% difference in mean
change in muscle strength between two groups over a 6-month
period. This 4% larger difference over placebo was determined
to be equivalent to arresting disease progression with the drug on
trial. Based on trial experience, Muscle Study Group 2004 calculated that a 2-arm, 6-month intervention would require 208 participants per group to detect the arrest of disease progression using
QMT with 90% power, a 2-tailed t-test, and significance level of
5%.
Multicentre recruitment, pooling of trial results, or both, might
allow for the accumulation of sufficient data for a more robust
answer as to the efficacy of treatment for IBM. However, we still
expect differences in both methodologies and the type of intervention to affect treatment effect estimates and the validity of results.
Across the studies included in this review, meta-analysis was compromised by the fact that outcome measurement was not standardised to measure the cardinal effects of interest, namely muscle weakness, atrophy, and functional impairment. Additionally,
some studies used normalised MDs for assessing change in muscle
strength.

For muscle strength testing, it would be helpful to standardise appropriate test methodology (for example, manual or quantitative
measurements (or both), specification and number of muscles or
muscle actions tested, and the detection of a minimal clinically
important difference) for use in research trials. The potential for
harm resulting from treatment also needs to be carefully considered; none of the included studies defined what constituted an
adverse effect, although drug treatments were associated with adverse effects of variable severity. Most of the studies also did not
specify the methods used to monitor adverse effects. Analysis of
treatment effect can risk bias towards a focus on favourable outcome measures in the absence of sufficient information on conduct and reporting of adverse events (Loke 2007).
None of the completed trials made reference to responsiveness or a
minimal clinically important difference for any outcome measure
in relation to disease progression. The validation of trial outcome
measures, where reported, was also not performed specifically in
an IBM population.
In terms of comparing future clinical trials in IBM, it will be important to minimise the differences in inclusion and exclusion criteria applied; this review found that trials used a range of criteria
regarding comorbidity and concomitant treatment that could have
a fundamental impact on study outcomes. Some have argued that
insistence on pathological criteria for the inclusion of IBM in clinical trials may result in such trials attempting to treat participants
who have more advanced, and therefore inherently less treatable,
disease. Currently proposed diagnostic criteria reduce the emphasis on pathological criteria with the aim of allowing recruitment
of participants earlier in the course of their disease. However, this
strategy is subject to verification, and currently there are no trials
that apply these newer criteria for IBM.

Costs
UK costs for treatment with the interventions used in the included
studies would be:
• Interferon beta-1a (Avonex): injection, 60 µg (12 million
units)/mL, net price 0.5 mL (30 µg, 6 million-unit) prefilled
syringe = GBP 163.50 (BNF 2014).
• Methotrexate: tablets, 2.5 mg, net price 24-tablet pack =
GBP 2.22; 10 mg, net price 100-tablet pack = GBP 37.06 (BNF
2014).
• Azathioprine: tablets, 50 mg, 56-tablet pack = GBP 3.42
(BNF 2014).
• Intravenous immunoglobulin: based on 2 g/kg in 70 kg
man = GBP 3906 to 4900 (DH 2011).
• Oxandrolone: a price from 2000 of USD 4 per 2.5 mg
tablet (Beaston-Blaakman 2007). In the UK, injection,
nandrolone decanoate 50 mg/L, net price 1 mL ampoule = GBP
3.17 by deep intramuscular injection, 50 mg every 3 weeks
(BNF 2014).
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Intervention treatment costs per person over a six-month period
were estimated to be greatest for IVIg (approximately GBP 15,000)
followed by IFN beta-1a therapy, and with markedly lower costs
for oxandrolone by intramuscular injection, AZA, and MTX treatment.

Potential biases in the review process
We chose to express the primary outcome as the percentage change
in compound MMT over time because it is a widely used approach
to muscle strength assessment in clinical research. However, percentage change calculation was rarely feasible using the available
data, and two trials reported normalised data instead. Our percentage figures related to group-level changes, but these are likely
to be different from those calculated using absolute data from individuals. We expected the data to be subject to uncertainty in
relation to clinical and statistical heterogeneity and significance.
Using absolute changes would be preferable, but these were not
retrievable across all trials in the review. Also, to calculate mean
change in absolute MMT scores might have required that only
those muscles tested by all studies and scaled to the same MRC
grading were included in analysis.
Another potential bias in the review process was in the type of
selected outcome measures. Our selected functional impairment
outcome measures were restricted to specific single-item tasks,
while inflammatory and pathological biomarkers were not analysed at all. Nevertheless, our data extraction did suggest that included trials inconsistently assessed or reported those additional
functional, inflammatory, and pathological outcomes.
Some of the review authors were investigators in included trials.
A non-conflicted review author performed independent data extraction if any review author had potential conflicts of interest, for
example through involvement in an included study.
A further limitation of the review was that the review methods
were unlikely to adequately detect serious, rare adverse events. We
therefore discussed adverse events described in other sources in the
Discussion.

Agreements and disagreements with other
studies or reviews
The results of this systematic review confirmed previous observational study and review findings that there are no established, evidence-based treatments for IBM as yet (Benveniste 2011;
Breithaupt 2013; Machado 2013b). The small sample sizes and
short duration of clinical trials are recognised as major limitations
in the evaluation of treatment efficacy in this muscle condition
(Breithaupt 2013; Fergusson 2005). In terms of assessment, MMT
scores of muscle strength are widely used in research and clinical practice, but further development of sensitive outcome measures is advocated (Breithaupt 2013; Machado 2013). Studies in-

cluded in this review used different methodological and analytical
approaches to assess muscle strength and applied a range of secondary outcome measures. Such variations in methods and outcome measures hindered the pooling of trial data to contribute to
the evidence base. As part of a systematic review in neurological
conditions, Fergusson 2005 analysed the same three IVIg trials for
IBM as in our review; like us, they were unable to come to a conclusion about the efficacy of IVIg from the available data. Fergusson
2005 similarly elected not to perform pooled analysis due to between-trial differences in methodology. Interestingly, the benefit
of IVIg in chronic inflammatory demyelinating polyneuropathy
(CIDP) was identified using a disability scale, as was the benefit
Walter 2000 showed for IVIg in IBM, using the Neuromuscular
Symptom and Disability Functional Score. Such evidence perhaps
argues for the use of disability scales in future IBM trials. However, Fergusson 2005 also emphasised that evidence of benefit still
does not necessarily support IVIg as a first-line treatment owing
to other factors, including adverse events and cost.
Evidence of mitochondrial abnormalities in IBM that are in excess
of those seen with normal ageing may suggest another range of
therapeutic options, but there are currently no known effective
treatments for primary mitochondrial disease (Pfeffer 2012). Similarly, currently there are no drugs with the therapeutic potential
to arrest or slow down the degenerative pathology seen in IBM
(Breithaupt 2013). A common issue highlighted across Cochrane
intervention reviews in muscle disease is the quality of study design and paucity of RCTs, emphasising ongoing problems with
sample size and risk of bias (Hill 2004; Pfeffer 2012; Voet 2013).
The validity of the evidence base also appears to be limited by a
lack of standardisation in the collection, evaluation, and reporting
of data. This systematic review identified specific quality issues in
clinical trials of people with IBM, which should encourage investigators to validate outcome measures and ensure standardisation
of trial procedures.
Only one of the studies included in this review measured swallowing function, which we did not include as a predefined outcome measure. In the future a Cochrane review of treatment for
swallowing difficulties in chronic muscle disease will include IBM
(Hill 2004). In terms of ongoing drug trials for IBM, we identified
an RCT of bimagrumab (BYM338), which has been developed to
target molecular pathways involved in muscle growth, and which
we may include in a future review. An RCT of simvastatin is also
pending completion.

AUTHORS’ CONCLUSIONS
Implications for practice
Trials of interferon beta-1a and methotrexate provided moderatequality evidence of having no effect on the progression of sporadic
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inclusion body myositis although we cannot exclude clinically relevant effects. An open trial of anti T-lymphocyte immunoglobulin
combined with methotrexate versus methotrexate provided very
low-quality evidence in favour of the combined therapy, based on
the percentage change data given. We were unable to draw conclusions from trials of intravenous immunoglobulin, oxandrolone,
and azathioprine plus methotrexate versus methotrexate. Overall
trial design limitations and selective reporting made it difficult to
say whether or not any of the drug treatments were effective in
arresting or slowing disease progression. Any decision to prescribe
these treatment regimens in the absence of evidence for or against
benefit will need to consider the potential adverse effects and the
cost of medication.

Implications for research
More randomised controlled trials are needed on which to base
treatment decisions. Such trials will need to recruit larger numbers
and be of longer duration than has hitherto been the case, in order

to derive definite conclusions as to the benefit or otherwise of any
intervention. Standardisation of the trial protocols using agreed
diagnostic criteria and validated, responsive outcome measures for
such trials is also necessary. Finally, we recommend a cost-utility
analysis to assist decision-making in the treatment of IBM.
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CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]
Badrising 2002
Methods

Randomised, placebo-controlled, parallel-group, double-blind trial

Participants

44 randomised participants (11 female)
Treated group mean age: 68 ± 8 years; mean duration of symptoms: 9 ± 5 years
Placebo group mean age: 69 (± 7) years; mean duration of symptoms: 11 (± 7) years
Inclusion criteria: diagnostic criteria for definite or probable IBM; sufficient residual
muscle strength to evaluate changes; absence of risk factors for MTX-induced toxicity;
no use of immunosuppressive therapy for at least 6 weeks before the study; no previous
use of MTX; no use of medication interfering with MTX pharmacokinetics or pharmacodynamics; absence of severe dysphagia interfering with oral medication use
Exclusion criteria: unspecified.

Interventions

MTX versus placebo for 48 weeks

Outcomes

Primary outcome measure(s)
• Change in QMT sum scores
14 muscle groups were tested, but the actual muscles tested was not reported
Secondary outcome measure(s)
• Change in MMT sum scores
32 muscle groups were tested by MMT using a 5-point MRC scale, but the actual muscles
tested was not reported
• Change in level of function, assessed by 3 activity scales: Barthel Index;
Rivermead Mobility Index; Brooke’s grading system
• Change in participants’ subjective assessment of muscle strength
• Change in serum CK activity levels
• Adverse event

Notes
Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

The investigators describe a random component in the sequence generation process:
“Patients were randomly assigned, using
a computer-generated schedule...The randomization schedule used random numbers in permuted blocks of 4”

Allocation concealment (selection bias)

Central allocation: “The code was concealed by the pharmacy and broken after
assessment of all patients”

Low risk

Treatment for inclusion body myositis (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

39

Badrising 2002

(Continued)

Blinding of participants and personnel Low risk
(performance bias)
All outcomes

Blinding procedures undertaken following allocation concealment: “To enhance
blinding, all patients were requested to decrease their 20mg dosage by 2.5mg without
explanation after routine laboratory evaluations for 3 months. After blood assessments, the dosage was restored to 20mg per
week”

Blinding of outcome assessment (detection Low risk
bias)
All outcomes

Blinding of outcome assessment described following allocation concealment:
“A blinded assessor (JV) monitored patients with regard to treatment schedules.
..Another blinded assessor (UB) evaluated
the QMT and MMT measurements and
patients’ opinions concerning the state of
muscle weakness”

Incomplete outcome data (attrition bias)
All outcomes

Low risk

Number of participants randomised and
reasons for missing data stated; all subjects
including dropouts analysed with average
values and data variance clearly specified

Selective reporting (reporting bias)

Low risk

The study protocol is not available, but outcomes prespecified in the methods are all
reported in the results

Other bias

Low risk

Minimisation of other treatment effects
clearly specified: “no use of immunosuppressive therapy for at least 6 weeks before
the study, no previous use of MTX, no use
of medication interfering with MTX pharmacokinetics or pharmacodynamics, and
absence of severe dysphagia interfering with
oral medication use”

Dalakas 1997
Methods

Randomised, double-blind, placebo-controlled, cross-over study

Participants

19 randomised participants (gender unspecified)
IVIg group mean age: 61.2 (42 to 74) years; mean disease duration: 5.6 (3 to 10) years
Placebo group mean age: 66.1 (35 to 76) years; mean disease duration: 7.4 (4 to 16)
years
Inclusion criteria: diagnostic criteria of IBM; active disease characterised by progressive
muscle weakness; impaired ability to perform fully the ADL; absence of another systemic
illness
Exclusion criteria: coronary artery disease; immunoglobulin A deficiency; kidney dys-
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(Continued)

function; bedridden patients
Interventions

IVIg versus placebo for 3 months

Outcomes

Primary outcome measure(s)
• Change in compound MMT scores
MMT was completed for 26 muscle groups and muscle group actions bilaterally: deltoid;
biceps brachii; triceps brachii; brachioradialis; wrist extensors; wrist flexors; iliopsoas;
gluteus maximus; quadriceps femoris; hamstrings; neck, finger and foot extension and
flexion. However, analysis was completed on only 10/26 muscle groups as data were not
always available. The 10 selected muscle groups were graded using a modified (0 to 10)
MRC scale (Brooke 1983), with a total maximal MRC score of 200.
Secondary outcome measure(s)
• Change in QMT sum scores
• Change in upper and lower limb MRC scores from baseline (limb by limb
analysis)
• Change in participants’ assessment of their response to therapy
Swallowing function was also investigated by ultrasound assessment of the duration of
both wet and dry swallowing

Notes
Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

The investigators describe a random component in the sequence generation process:
“The patients were assigned to receive IVIg
or placebo by a block-randomization procedure”

Allocation concealment (selection bias)

Central allocation: “Randomization was
performed at the pharmacy”

Low risk

Blinding of participants and personnel Unclear risk
(performance bias)
All outcomes

Insufficient information to permit judgement: “The principal investigator, the
physicians, nurses, physical therapists, and
statistician were unaware of which treatment was administered” but “Sixteen of
the 19 patients correctly identified the period during which they received placebo or
IVIg”

Blinding of outcome assessment (detection Unclear risk
bias)
All outcomes

Insufficient information to permit judgement: blinding not described fully following allocation concealment, as above
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Incomplete outcome data (attrition bias)
All outcomes

High risk

No SD values included to assess for a clinically relevant bias in observed effect size.
No statistical analysis for the incidence of
adverse events was completed

Selective reporting (reporting bias)

High risk

Data largely presented graphically and with
discrepancies between data points and figures reported elsewhere. No study protocol
available

Other bias

High risk

Randomisation was broken by giving participants the option to cross over intervention. There was also a potential carry-over
effect of previous treatment(s): “Nineteen
of the patients had been treated previously
with high-dose prednisone or therapeutic doses of another immunosuppressant
(methotrexate, azathioprine) for at least 4
to 6 months.” There was also a minimum
washout period of 1 month, which may not
be long enough to exclude a carry-over effect

Dalakas 2001
Methods

Randomised, double-blind, placebo-controlled study

Participants

37 randomised participants (gender unspecified)
Treated group mean age: 68.21 (no SD or range) years
Placebo group mean age: 68.35 (no SD or range) years. Duration of symptoms not given
Inclusion criteria: diagnostic criteria for sporadic IBM; active disease characterised by
progressive muscle weakness that impaired ability to perform independently various
activities of daily living such as walking without falls, dressing, buttoning, or climbing
up stairs; ambulatory independently or with assistance
Exclusion criteria: wheelchair-bound patients; coronary artery disease; immunoglobulin
A deficiency; kidney dysfunction; any systemic illness

Interventions

IVIg and prednisone versus placebo and prednisone for 3 months

Outcomes

Primary outcome measure(s)
• Change in MMT sum scores
MMT was completed for 13 muscle groups and muscle group actions bilaterally (although 12 specified): deltoid; biceps brachii; triceps brachii; brachioradialis; wrist extensors; wrist flexors; iliopsoas; gluteus maximus; quadriceps femoris; hamstrings; foot
extension or flexion. Muscle strength was graded on a modified (0 to 10) MRC scale
(Brooke 1983).
• Change in QMT sum scores
QMT was examined for the following muscle group actions: shoulder abduction; forearm
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flexion and extension; hip flexion; leg extension and flexion; foot extension
Secondary outcome measure(s)
• Change in participants’ assessment of their response to therapy, categorised as “felt
better and performed more”, “felt weaker”, or “no change”
Histological features were also assessed in repeated biopsies
Notes
Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

The investigators describe a random component in the sequence generation process:
“The patients were assigned to receive IVIg
or placebo by a block-randomization procedure”

Allocation concealment (selection bias)

Central allocation: “Randomization was
performed at the pharmacy”

Low risk

Blinding of participants and personnel Unclear risk
(performance bias)
All outcomes

Insufficient information to permit judgement: “The principal investigator, the
physicians, nurses, physical therapists, and
statisticians were unaware of which type
of the IV infusion was administered” and
based on participants’ own assessment “no
apparent signs to unblind any of the patients were observed.” However, only the
assessor of QMT and not MMT is confirmed to have remained blinded, suggesting that blinding of key personnel could
have been broken

Blinding of outcome assessment (detection Unclear risk
bias)
All outcomes

Insufficient information to permit judgement: as above, only the assessor of QMT
is confirmed to have “remained blinded”

Incomplete outcome data (attrition bias)
All outcomes

Low risk

Number of participants randomised and
reasons for missing data stated; 1 dropout
(died from myocardial infarction on
placebo infusion) not analysed. No statistical analysis for the incidence of adverse
events was completed

Selective reporting (reporting bias)

Low risk

The study protocol is not available, but outcomes prespecified in the methods are all
reported in the results
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Unclear risk

Insufficient information to permit judgement, but potential carry-over effect of previous treatment(s): “Several patients had
been treated previously with high-dose
prednisone or therapeutic doses of another immunosuppressant (methotrexate,
azathioprine), but they had not been taking
any such medicine up to 3 months before
enrollment”

Leff 1993
Methods

Open, randomised, cross-over trial

Participants

11 randomised participants (2 female)
Mean age: 54 ± 8 years (calculated from table). Duration of symptoms not given
Inclusion criteria: Bohan and Peter’s criteria for definite myositis and biopsy-proven IBM
with typical light microscopic changes; signs of active inflammatory muscle disease;
progressive weakness refractory to therapy; weak enough to have at least 2 muscle groups
graded 3 or less on a scale of 0 to 5 by manual muscle testing; reduction of at least 1
functional level below normal in at least 1 activity group on an assessment of the ADL
for functional capabilities
Exclusion criteria: severe intercurrent illness; cancer; infection; past history of alcohol
abuse; pregnancy; abnormal renal or hepatic function. “Concurrent use of alcohol or
nonsteroidal anti-inflammatory drugs was forbidden”

Interventions

Azathioprine and MTX versus MTX for 6 months

Outcomes

• Categorical change in muscle strength, defined as “improvement”, “stabilisation”,
or “worsening”, based on MMT scores
Investigators graded MMT using a 6-point MRC scale. They examined 7 muscle groups
or muscle group actions bilaterally: gluteus maximus and medius; iliopsoas; quadriceps;
deltoid; trapezius; biceps brachialis; as well as neck flexors and extensors unilaterally. The
maximum MRC sum score was reported to be 80. Trial authors defined “improvement”
and “worsening” as a change of at least 1 MMT grade in 2 muscle groups and a net
change in score of at least 2 points on MMT. They defined “stabilisation” as any result
other than “improvement” or “worsening”
• Categorical change in level of function, defined as “improvement”, “stabilisation”,
or “worsening”, using an ADL score
ADL were assessed using a modified Convery Assessment Scale (Convery 1977); 4 items
relating to feeding, grooming, wheelchair use, and perineal care were deleted from the
original questionnaire, and a question about reaching above eye level was added into the
scale. “Improvement” was defined as a net increase of at least 1 functional level in at
least 1 category in the ADL score. A “worsening” clinical status was defined as similar
decreases in ADL scores, and “stabilisation” was any result other than “improvement” or
“worsening”
No primary outcome measure was specified. Other pathophysiological measures included laboratory investigations (CK, aldolase, lactate dehydrogenase, aspartate amino-
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transferase and alanine aminotransferase levels), gradings for MRI and inflammatory
changes in muscle biopsies
Notes

Single-centre study

Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Unclear risk
bias)

No information given.

Allocation concealment (selection bias)

No information given.

Unclear risk

Blinding of participants and personnel High risk
(performance bias)
All outcomes

Open-label trial

Blinding of outcome assessment (detection High risk
bias)
All outcomes

Open-label trial

Incomplete outcome data (attrition bias)
All outcomes

High risk

Reason for missing outcome data likely to be related to true outcome: “All patients received 6
months of each regime unless: a) worsening was
noted after 3 months; b) after 3 months of the second (or cross-over) therapy no improvement was
noted; or c) unacceptable side effects occurred”.
While “most patients received the full 6 months
of each regime” this is not quantified; there is
also evidence of adverse effects leading to exclusion that might have been underestimated in seriousness and without intention-to-treat analysis: “.
..2 patients underwent cholecystectomies during
the study for acute cholecystitis and subsequently
were unable to continue because they experienced
gastrointestinal intolerance and/or abnormal liver
function tests when they resumed treatment with
the drugs”. No statistical analysis for the incidence
of adverse events was completed

Selective reporting (reporting bias)

Unclear risk

Insufficient information to permit judgement: numerical strength scale interpreted only by subjective improvement, stabilisation, or worsening

Other bias

High risk

After the first treatment period, participants were
observed for worsening before beginning the second period, breaking randomisation. There was
also a potential carry-over effect of previous treat-
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ment(s): “For 2 weeks before protocol entry, the
prednisone dose was held stable, and apheresis or
immunosuppressive therapy was not given”

Lindberg 2003
Methods

Open randomised controlled trial

Participants

11 randomised participants (3 female)
ATG group mean age: 72 ± 7.0 years; mean duration of disease: 7.2 ± 3.4 years
MTX group mean age: 64.8 ± 4.0 years; mean duration of disease: 9.8 ± 5.0 years
Inclusion criteria: the morphological criteria of IBM diagnosis included inflammation,
rimmed vacuoles and intracellular amyloid deposits or 15 to 20 nm filaments
Exclusion criteria: unspecified.

Interventions

MTX and ATG versus MTX (plus leucovorin) for 12 months

Outcomes

Primary outcome measure(s)
• Change in muscle strength using QMT and handgrip
The primary outcome measure was the relative change of mean overall muscle strength,
expressed as a percentage. Maximal voluntary muscle strength was measured with a
handheld myometer and was used to assess the following muscle group actions: elbow
flexion and extension; wrist dorsal extension; hip flexion; knee extension. Handgrip
mean volumetric contraction was also quantitated using hand-held myometry
Other outcome measures were blood levels of CK and T lymphocyte subsets. Muscle
biopsies were done at the start and end of the trial, and inflammation in the tissue was
graded visually
MVIC was measured using a hand-held myometer.

Notes
Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Unclear risk
bias)

No information given.

Allocation concealment (selection bias)

No information given.

Unclear risk

Blinding of participants and personnel High risk
(performance bias)
All outcomes

Open-label trial

Blinding of outcome assessment (detection High risk
bias)
All outcomes

Open-label trial
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Incomplete outcome data (attrition bias)
All outcomes

Low risk

Number of participants randomised and reasons
for missing data stated; last data carried forward
with average values and variance clearly specified.
No statistical analysis for the incidence of adverse
events was completed

Selective reporting (reporting bias)

Unclear risk

Insufficient information to permit judgement: percentage change in muscle strength data given but
no actual scores

Other bias

Unclear risk

Insufficient information to permit judgement, but
potential carry-over effect of previous treatment(s)

Machado 2013
Methods

Randomised, double-blind, placebo-controlled trial

Participants

24 participants (7 female) fulfilling Griggs criteria for definite or probable IBM

Interventions

Arimoclomol versus placebo for 16 weeks

Outcomes

Primary outcome(s)
• Adverse event reporting (safety and tolerability)
Secondary outcomes(s)
• IBM functional rating scale (IBMFRS)
• MMT
• MVICT
• Fat-free mass percentage (DEXA)
• HSP70 levels in muscle biopsy tissue (adjusted to myosin content)

Notes

Abstract only.

Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Unclear risk
bias)

Stated to be randomised. No further information.

Allocation concealment (selection bias)

Abstract only. Not described.

Unclear risk

Blinding of participants and personnel Unclear risk
(performance bias)
All outcomes

“Double-blind, placebo-controlled”. No
further information.

Blinding of outcome assessment (detection Unclear risk
bias)
All outcomes

“Double-blind, placebo-controlled”. No
further information.
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Incomplete outcome data (attrition bias)
All outcomes

Unclear risk

Abstract only. Unable to assess.

Selective reporting (reporting bias)

Unclear risk

No protocol. Unable to assess.

Other bias

Unclear risk

None identified.

Muscle Study Group 2001
Methods

Randomised, double-blind, placebo-controlled, parallel-group trial

Participants

30 randomised participants (11 female)
IFN beta-1a (Avonex)-treated group: mean age: 65.7 ± 9.3 years; age at onset: 57.0 ±
10.0 years
Placebo-treated group mean age: 65.9 ± 10.3 years; age at onset: 57.3 ± 9.3 years
Inclusion criteria: diagnostic criteria for definite or probable IBM; able to walk independently 15 feet (cane, walkers, orthoses allowed); age > 30 to ≤ 80 years; women
of childbearing potential must have a reliable method of birth control; must not have
received immunosuppressive agents for at least 3 months prior to enrolment; able to give
informed consent
Exclusion criteria: presence of any one of the following medical conditions: uncontrolled
diabetes mellitus; congestive heart disease; symptomatic cardiomyopathy; symptomatic
coronary artery disease; cancer other than skin cancer < 5 years previously; multiple
sclerosis or other chronic serious medical illness; presence of any of the following on
routine blood screening: white blood cell count < 3000, platelets < 100,000, hematocrit
< 30%, blood urea nitrogen > 30 mg%, symptomatic liver disease with serum albumin
< 3 g/dL, prothrombin time or partial thromboplastin time > upper range of normal;
presence of major depression on day of screening or history of attempted suicide; forced
vital capacity < 50% of predicted; pregnancy or lactating; history of noncompliance with
other therapies; other disease that required immunosuppressive therapy within the last
12 months; coexistence of other neuromuscular disease

Interventions

IFN beta-1a versus placebo for 24 weeks

Outcomes

• Change in muscle strength using QMT, handgrip, and MMT
QMT was performed using the QMA system; 5 muscle groups or muscle group actions
were tested on each side: biceps; triceps; quadriceps; hamstrings, and ankle dorsiflexion.
These results were expressed as the average number of SD units from predicted normal
strength, given the age, gender, and height of the participant. Handgrip MVIC was also
quantitated using myometry but with a hand-held device rather than the fixed myometer
used for other muscle tests
MMT tested a total of 34 (unspecified) muscle groups using a 6-point MRC scale
• Change in lean body mass using DEXA
• Change in level of function, assessed by the following: Purdue pegboard test; time
to rise from chair; time to walk 15 feet; ALS-FRS; components of the SF-36
• Change in participants’ reporting of symptoms on the Beck Depression Inventory
• Adverse events
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Measurements of biologic effects of treatment were also performed: serum neutralising
antibodies and serum neopterin levels
No primary outcome measure was specified.
Notes
Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

The investigators describe a random component in the sequence generation process: “a computer-generated randomization plan developed by the Biostatistics
Centre at the University of Rochester (NY)
. The randomization was stratified by center and included blocking”

Allocation concealment (selection bias)

Central allocation: “Only the biostatistics
programmer and the pharmacist at each
site...had access to the treatment assignment”

Low risk

Blinding of participants and personnel Unclear risk
(performance bias)
All outcomes

Insufficient information to permit judgement: active injections may have been more
likely to cause local reactions; all participants treated with non-steroidal anti-inflammatory drug to mask systemic reactions from active compound

Blinding of outcome assessment (detection Unclear risk
bias)
All outcomes

Insufficent information to permit judgement: blinding of assessors not described
fully following allocation concealment

Incomplete outcome data (attrition bias)
All outcomes

Low risk

Number of participants randomised and
reasons for missing data stated; intentionto-treat principle stated with no computation of missing data from 1 dropout. No
statistical analysis for the incidence of adverse events was completed

Selective reporting (reporting bias)

Low risk

The study protocol is not available, but outcomes prespecified in the methods are all
reported in the results

Other bias

Unclear risk

Insufficient information to permit judgement, but potential carry-over effect of previous treatment(s), although inclusion criteria state that participants “must not have
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received immunosuppressive agents for at
least 3 months prior to enrollment”

Muscle Study Group 2004
Methods

Randomised, double-blind, placebo-controlled, parallel-group trial

Participants

30 randomised participants (11 female)
IFN beta-1a (Avonex)-treated group mean age: 64.9 ± 6.9 years; age at onset: 57.5 ± 8.
4 years
Placebo-treated group mean age: 64.9 ± 7.3 years; age at onset: 55.5 ± 7.1 years
Inclusion and Exclusion criteria as per Muscle Study Group 2001

Interventions

IFN beta-1a versus placebo for 24 weeks

Outcomes

As per Muscle Study Group 2001

Notes
Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

The investigators reference a random component in the sequence generation process:
“Randomization procedures were identical
to those used in our previous trial”

Allocation concealment (selection bias)

Central allocation: “...only the biostatistics
programmer and site pharmacists had access to the treatment assignments”

Low risk

Blinding of participants and personnel Unclear risk
(performance bias)
All outcomes

Insufficient information to permit judgement: active treatment injections may have
been more likely to cause local reactions;
all participants treated with non-steroidal
anti-inflammatory drug to mask systemic
reactions from active compound

Blinding of outcome assessment (detection Unclear risk
bias)
All outcomes

Insufficient information to permit judgement: blinding of assessors not described
fully following allocation concealment

Incomplete outcome data (attrition bias)
All outcomes

Number of participants randomised and
reasons for missing data stated; intention-to-treat principle stated, although data
from only 1 of 3 dropouts were carried forward for analysis

Low risk
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Selective reporting (reporting bias)

Low risk

The study protocol is not available, but outcomes prespecified in the methods are all
reported in the results

Other bias

Unclear risk

Insufficient information to permit judgement, but potential carry-over effect of previous treatment(s), although inclusion criteria as per their previous study specified
that participants must not have received
immunosuppressive agents for at least 3
months prior to enrolment

Rutkove 2002
Methods

Block-randomised, double-blind, placebo-controlled, cross-over trial

Participants

19 randomised participants, but baseline characteristics provided for 16 participants who
completed the trial (2 female). Overall mean age: 68.5 years (no SD or range). Mean
duration of disease unspecified
Inclusion criteria: pathological criteria for a definite diagnosis of IBM; consistent clinical
and laboratory features including prominent weakness of quadriceps, weakness of wrist
flexors greater than extensors, age older than 40 years, and elevated serum CK, without
evidence of other significant neurologic problems
Exclusion criteria: history of prostate or breast cancer; haemodialysis; congestive heart
failure; atypical or restricted forms of IBM; a coexisting neuromuscular condition; uncontrolled hypertension; history of substance abuse; currently taking warfarin; IVIg use
within 2 months or currently on an immunosuppressive drug regimen including corticosteroids

Interventions

Oxandrolone versus placebo for 12 weeks

Outcomes

Primary outcome measure(s)
• Change in QMT sum scores, using MVICT
Using a fixed myometer, whole body MVICT was measured bilaterally for muscle group
actions including: shoulder flexion and extension; elbow flexion and extension; knee
flexion and extension; foot dorsiflexion. Handgrip strength was also evaluated quantitatively by MVICT but using a hand-held myometer
Secondary outcome measure(s)
• Change in MMT sum scores
Whole body MMT was graded using an expanded 1-5 MRC scale. 13 bilateral muscle
group actions were assessed: shoulder external rotation and abduction; elbow flexion and
extension; wrist flexion and extension; hip flexion, abduction and presumed adduction
(written as “abduction” in publication); knee flexion and extension; foot plantar flexion
and dorsiflexion. 2 unilateral muscle group actions were also assessed: head flexion and
extension. The maximum reported MRC score was 140
• Change in upper and lower extremity MVICT scores
• Change in upper and lower extremity MMT scores
• Change in level of function, assessed by the timed get-up-and-go test, 6-minute
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walk, and stair climb
• Change in lean body mass (skin fold measurements) and body mass index
Notes
Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

The investigators describe a random component in the sequence generation process:
“...a four-person block-randomization procedure”

Allocation concealment (selection bias)

Central allocation: pharmacy-generated

Low risk

Blinding of participants and personnel Unclear risk
(performance bias)
All outcomes

Insufficient information to permit judgement: blinding not described fully following allocation concealment: “the principal investigator, coinvestigators, nurses
and physical therapists were blinded to the
treatment assignments...and the randomization code was maintained in the hospital research pharmacy”, but 8/13 participants “...correctly reported that they were
on drug...”

Blinding of outcome assessment (detection Low risk
bias)
All outcomes

Insufficient information to permit judgement: possible unblinding of outcome assessment following allocation concealment
indicated, as above

Incomplete outcome data (attrition bias)
All outcomes

Unclear risk

Insufficient information to permit judgement: baseline characteristics not available
for all randomised participants, although
reasons for missing data given. Also, nonparametric data are reported due to concerns about the normality of the data, but
no normality test results are given

Selective reporting (reporting bias)

Low risk

The study protocol is not available, but outcomes prespecified in the methods are all
reported in the results

Other bias

Unclear risk

Insufficient information to permit judgement, but potential carry-over of previous
treatment(s), although “Patients were...excluded if they had received IVIg within 2
months or were currently on an immuno-
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suppressive drug regimen including corticosteroids”
Walter 2000
Methods

Block-randomised, double-blind, placebo-controlled, cross-over trial

Participants

22 randomised participants (8 female). Mean age: 59 ± 14 years; disease duration: 1 to
14 years
Inclusion criteria: clinical and histological criteria for definite sporadic IBM
Exclusion criteria: stabilisation or improvement on current immunosuppressive therapy; severe coronary heart disease; renal insufficiency; intolerance to homologous immunoglobulins or human serum proteins; other relevant neuromuscular disorders; those
confined to bed or wheelchair for longer than 1 year

Interventions

IVIg versus placebo for 6 months

Outcomes

Primary outcome measure(s)
• Change in MMT sum scores
MMT was completed for the following muscle groups and muscle group actions bilaterally: deltoid; biceps brachii; triceps brachii; brachioradialis; hand flexion and extension; finger flexion and extension; knee flexion and extension; foot flexion and extension. 2 muscle group actions were tested unilaterally: neck flexion and extension. Muscle
strength was graded on a 0-6 MRC scale, with a total maximal score of 180. The change
in upper and lower extremity strength was also analysed as a subgroup
• Change in the Neuromuscular Symptom and Disability Functional Score
Secondary outcome measure(s)
• Change in arm outstretched time
• Change in participant’s assessment of improvement using visual analogue scales
for weakness and daily activities
Electromyographic tests to assess graded change in spontaneous activity were also performed

Notes
Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

The investigators describe a random component in the sequence generation process:
“block-randomization procedure”

Allocation concealment (selection bias)

Method of allocation concealment not described, but “the randomization code was
not broken until all patients completed the
study”

Low risk
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Walter 2000

(Continued)

Blinding of participants and personnel Unclear risk
(performance bias)
All outcomes

Insufficient information to permit judgement: blinding not described fully following allocation concealment

Blinding of outcome assessment (detection Unclear risk
bias)
All outcomes

Insufficient information to permit judgement: blinding not described fully following allocation concealment, although
authors retrospectively state that assessors
were blinded

Incomplete outcome data (attrition bias)
All outcomes

Unclear risk

Insufficient information to permit judgement: reasons not given for missing data
from 2 dropouts; all participant data carried forward for safety analysis, but only
completed data used for efficacy analysis;
also non-parametric statistical analyses performed, although both mean and median
data are reported in results and without
specification of SD or interquartile range

Selective reporting (reporting bias)

Unclear risk

Insufficient information to permit judgement: the primary outcomes specified in
the methods are not fully reported in the
results; authors do not compare IVIg versus
placebo periods

Other bias

Unclear risk

Insufficient information to permit judgement, but potential carry-over effect from
previous treatment(s): “Of the 22 patients
19 patients had previously been treated
with various drugs”. Also, “Physiotherapy
was administered to all patients in both
groups once or twice per week throughout
the entire trial” but was not assessed as part
of the therapeutic intervention

ADL: activities of daily living
ALS-FRS: Amyotrophic Lateral Sclerosis Functional Rating Scale
ATG: anti-T lymphocyte immunoglobulin
CK: creatine kinase
DEXA: dual energy X-ray absorptiometry
HSP70: 70 kilodalton heat shock protein
IFN: interferon
IVIg: intravenous immunoglobulin
MTX: methotrexate
MMT: manual muscle testing
MRC: Medical Research Council
MRI: magnetic resonance imaging
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MVICT: maximal voluntary isometric contraction testing
QMA system: Quantitative Muscle Assessment system
QMT: quantitative muscle testing
SD: standard deviation
SF-36: Short Form-36 Health Survey

Characteristics of excluded studies [ordered by study ID]

Study

Reason for exclusion

ACTRN12614000082606

Not a randomised trial

Amato 1994

Not a randomised trial

Arnardottir 2003

Not a randomised trial. Exercise-based intervention

Danon 1982

Not a randomised trial

Heikkillä 2001

Not a randomised trial. Exercised-based intervention

Joffe 1993

Not a randomised trial

Kosmidis 2013

Not a randomised trial

Lindberg 1994

Not a randomised trial

Mastaglia 1998

Non randomised trial

Mowzoon 2001

Not a randomised trial (1 participant with IBM)

NCT00079768

Not a randomised trial

NCT00917956

Not a randomised trial

NCT01519349

Not a randomised trial

Soueidan 1993

Not a randomised trial

IBM: inclusion body myositis
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Characteristics of ongoing studies [ordered by study ID]
EUCTR2007-004359-12-IT
Trial name or title

Simvastatin treatment in inclusion body myositis (IBM)

Methods

Randomised, controlled, open, parallel-group trial

Participants

People affected by IBM (diagnosis based on clinical, radiological, and pathological data); males and females;
aged 18 to 80 years; patients able to give informed consent

Interventions

Oral simvastatin

Outcomes

Main objective: safety and tolerability of simvastatin
Primary endpoint(s): improvement in functional indices

Starting date

2007

Contact information

Italian Medical Agency

Notes

-

NCT00001265
Trial name or title

Study and treatment of inflammatory muscle diseases

Methods

Observational study

Participants

People aged 16 and over with known or suspected idiopathic inflammatory myopathies or people with other
connective tissue diseases with weakness or myalgia for an inflammatory myopathy or other muscle process

Interventions

None specified

Outcomes

None specified

Starting date

August 1991

Contact information

National Institutes of Health Clinical Center

Notes
NCT01423110
Trial name or title

Efficacy, safety and tolerability of BYM338 in patients with sporadic inclusion body myositis

Methods

Double-blind, parallel assignment, placebo-controlled study

Participants

People aged 40 to 80 years old with sporadic IBM
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NCT01423110

(Continued)

Interventions

BYM338 or placebo

Outcomes

Primary outcome measures: effect of BYM338 on thigh muscle volume by MRI (after 8 weeks’ treatment):
change in thigh muscle volume
Secondary outcome measures: effect of BYM338 on muscle function by timed get-up-and-go test (after 8
weeks’ treatment): change in muscle function measured on scale by test results

Starting date

August 2011

Contact information

Novartis Pharmaceuticals

Notes

Study identifier: CBYM338X2205

IBM: inclusion body myositis; MRI: magnetic resonance imaging
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DATA AND ANALYSES

Comparison 1. Interferon beta-1a versus placebo

Outcome or subgroup title
1 Normalised change in muscle
strength over baseline at 6
months
1.1 MSG 2001
1.2 MSG 2004
2 Percentage change over baseline
in muscle mass at 6 months
2.1 MSG 2001
2.2 MSG 2004

No. of
studies

No. of
participants

2

58

Mean Difference (IV, Random, 95% CI)

-0.06 [-0.15, 0.03]

1
1
2

30
28
58

Mean Difference (IV, Random, 95% CI)
Mean Difference (IV, Random, 95% CI)
Mean Difference (IV, Random, 95% CI)

-0.09 [-0.20, 0.02]
0.0 [-0.16, 0.16]
0.22 [-1.69, 2.13]

1
1

30
28

Mean Difference (IV, Random, 95% CI)
Mean Difference (IV, Random, 95% CI)

0.95 [-1.86, 3.76]
-0.41 [-3.02, 2.20]

Statistical method

Effect size

Comparison 2. Methotrexate versus placebo

Outcome or subgroup title

No. of
studies

No. of
participants

1 Significant adverse events

1

44

Statistical method
Risk Ratio (M-H, Random, 95% CI)

Effect size
8.76 [1.19, 64.28]

Comparison 3. Anti-T lymphocyte + methotrexate versus methotrexate

Outcome or subgroup title
1 Percentage change from baseline
(QMT) at 12 months

No. of
studies

No. of
participants

1

11

Statistical method
Mean Difference (IV, Fixed, 95% CI)
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Effect size
12.5 [2.43, 22.57]

58

Analysis 1.1. Comparison 1 Interferon beta-1a versus placebo, Outcome 1 Normalised change in muscle
strength over baseline at 6 months.
Review:

Treatment for inclusion body myositis

Comparison: 1 Interferon beta-1a versus placebo
Outcome: 1 Normalised change in muscle strength over baseline at 6 months

Study or subgroup

IFN beta-1a

Mean
Difference

Placebo

N

Mean(SD)

N

Mean(SD)

14

-0.06 (0.15)

16

0.03 (0.16)

Weight

IV,Random,95% CI

Mean
Difference
IV,Random,95% CI

1 MSG 2001
Muscle Study Group 2001

Subtotal (95% CI)

14

67.4 %

16

-0.09 [ -0.20, 0.02 ]

67.4 % -0.09 [ -0.20, 0.02 ]

Heterogeneity: not applicable
Test for overall effect: Z = 1.59 (P = 0.11)
2 MSG 2004
Muscle Study Group 2004

Subtotal (95% CI)

15

-0.08 (0.22)

13

15

13

29

29

-0.08 (0.21)

32.6 %

0.0 [ -0.16, 0.16 ]

32.6 %

0.0 [ -0.16, 0.16 ]

Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)

Total (95% CI)

100.0 % -0.06 [ -0.15, 0.03 ]

Heterogeneity: Tau2 = 0.0; Chi2 = 0.82, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 1.30 (P = 0.19)
Test for subgroup differences: Chi2 = 0.82, df = 1 (P = 0.36), I2 =0.0%

-0.5

-0.25

Favours placebo
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Analysis 1.2. Comparison 1 Interferon beta-1a versus placebo, Outcome 2 Percentage change over baseline
in muscle mass at 6 months.
Review:
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Comparison: 1 Interferon beta-1a versus placebo
Outcome: 2 Percentage change over baseline in muscle mass at 6 months

Study or subgroup

IFN beta-1a

Mean
Difference

Placebo

N

Mean(SD)

N

Mean(SD)

14

0.1 (2.74)

16

-0.85 (4.92)

Weight

IV,Random,95% CI

Mean
Difference
IV,Random,95% CI

1 MSG 2001
Muscle Study Group 2001

Subtotal (95% CI)

14

16

46.4 %

0.95 [ -1.86, 3.76 ]

46.4 %

0.95 [ -1.86, 3.76 ]

53.6 %

-0.41 [ -3.02, 2.20 ]

Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
2 MSG 2004
Muscle Study Group 2004

Subtotal (95% CI)

15

-2.18 (3.06)

15

13

-1.77 (3.87)

53.6 % -0.41 [ -3.02, 2.20 ]

13

Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)

Total (95% CI)

29

29

100.0 %

0.22 [ -1.69, 2.13 ]

Heterogeneity: Tau2 = 0.0; Chi2 = 0.48, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Chi2 = 0.48, df = 1 (P = 0.49), I2 =0.0%

-10

-5

Favours placebo
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Analysis 2.1. Comparison 2 Methotrexate versus placebo, Outcome 1 Significant adverse events.
Review:
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Comparison: 2 Methotrexate versus placebo
Outcome: 1 Significant adverse events

Study or subgroup

MTX

Placebo

Risk Ratio
MH,Random,95%
CI

Weight

Risk Ratio
MH,Random,95%
CI

n/N

n/N

Badrising 2002

8/21

1/23

100.0 %

8.76 [ 1.19, 64.28 ]

Total (95% CI)

21

23

100.0 %

8.76 [ 1.19, 64.28 ]

Total events: 8 (MTX), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.13 (P = 0.033)
Test for subgroup differences: Not applicable

0.002

0.1

1

Favours MTX

10

500

Favours placebo

Analysis 3.1. Comparison 3 Anti-T lymphocyte + methotrexate versus methotrexate, Outcome 1
Percentage change from baseline (QMT) at 12 months.
Review:
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Comparison: 3 Anti-T lymphocyte + methotrexate versus methotrexate
Outcome: 1 Percentage change from baseline (QMT) at 12 months

Study or subgroup

ATG+MTX

Mean
Difference

MTX

N

Mean(SD)

N

Mean(SD)

Lindberg 2003

6

1.4 (9.8)

5

-11.1 (7.2)

Total (95% CI)

6

Weight

Mean
Difference

100.0 %

12.50 [ 2.43, 22.57 ]

100.0 %

12.50 [ 2.43, 22.57 ]

IV,Fixed,95% CI

IV,Fixed,95% CI

5

Heterogeneity: not applicable
Test for overall effect: Z = 2.43 (P = 0.015)
Test for subgroup differences: Not applicable

-50

-25

Favours MTX
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APPENDICES
Appendix 1. Cochrane Neuromuscular Disease Group Specialized Register (CRS) search strategy
#1 myositis NEAR “inclusion body” [REFERENCE] [STANDARD]
#2 (myositis NEAR “inclusion body”) AND (INREGISTER) [REFERENCE] [STANDARD]

Appendix 2. CENTRAL search strategy
#1 “inclusion body” NEAR myositis
#2 MeSH descriptor Myositis, Inclusion Body, this term only
#3 (#1 OR #2)

Appendix 3. MEDLINE (OvidSP) search strategy
Database: Ovid MEDLINE(R) <1946 to September Week 4 2014>
Search Strategy:
-------------------------------------------------------------------------------1 randomized controlled trial.pt. (389226)
2 controlled clinical trial.pt. (89867)
3 randomized.ab. (285185)
4 placebo.ab. (151031)
5 drug therapy.fs. (1748071)
6 randomly.ab. (201598)
7 trial.ab. (296312)
8 groups.ab. (1285103)
9 or/1-8 (3290339)
10 exp animals/ not humans.sh. (4016034)
11 9 not 10 (2802960)
12 exp Myositis, Inclusion Body/ or inclusion body myositis.tw. (1362)
13 11 and 12 (285)
14 remove duplicates from 13 (273)

Appendix 4. EMBASE (OvidSP) search strategy
Database: Embase <1980 to 2014 Week 40>
Search Strategy:
-------------------------------------------------------------------------------1 crossover-procedure.sh. (40306)
2 double-blind procedure.sh. (115609)
3 single-blind procedure.sh. (18869)
4 randomized controlled trial.sh. (350916)
5 (random$ or crossover$ or cross over$ or placebo$ or (doubl$ adj blind$) or allocat$).tw,ot. (1065137)
6 trial.ti. (163276)
7 or/1-6 (1198699)
8 (animal/ or nonhuman/ or animal experiment/) and human/ (1290984)
9 animal/ or nonanimal/ or animal experiment/ (3256545)
10 9 not 8 (2727334)
11 7 not 10 (1100982)
12 limit 11 to embase (913119)
13 exp Inclusion Body Myositis/ or inclusion body myositis.tw. (1908)
14 12 and 13 (97)
Treatment for inclusion body myositis (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

62

15 remove duplicates from 14 (95)

Appendix 5. Trials registry search strategy
inclusion body myositis

WHAT’S NEW
Last assessed as up-to-date: 7 October 2014.

Date

Event

Description

7 July 2015

Amended

Minor typographical corrections

HISTORY
Protocol first published: Issue 2, 1999
Review first published: Issue 6, 2015

Date

Event

Description

30 June 2015

Amended

Conflict of interest corrected

8 February 1999

New citation required and conclusions have changed
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For the protocol: MR and KL drafted earlier versions of the protocol with input from co-authors (Rose 1999; Rose 2007). KJ updated
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For the review stage:
• MR, KJ, MW, and JM assessed studies for inclusion.
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• MR and KL entered data; KJ checked data entry.
• MR and KJ assessed the risk of bias in included studies.
• RB assisted with analyses and drafted ‘Summary of findings’ tables.
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DIFFERENCES BETWEEN PROTOCOL AND REVIEW
We used The Cochrane ‘Risk of bias’ tool (Higgins 2011). We commented on the use of explicit diagnostic criteria, the quality of
outcome measures, and the power of the study to detect benefit where appropriate in the text.
We searched clinical trials registries for ongoing trials but did not carry out an up-to-date handsearch of conference abstracts.
We referred to Griggs 1995, Benveniste 2010, and Hilton-Jones 2010 for clinicopathologically defined IBM, but two trials referred to
clinicopathologically defined criteria using alternative references.
We renamed our outcome ‘significant side-effects’ as ‘significant adverse events’.
We defined significant adverse events as the incidence of withdrawals.
We clarified significant adverse events as the incidence of participant withdrawal from trials, with reasons explained where possible.
In line with the definition of an adverse event, we accepted that withdrawal might occur for reasons unspecified or unrelated to the
intervention.
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